b'<?xml version="1.0" encoding="utf-8"?>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\n<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">\n    \n    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />\n        <!-- AppResources meta begin -->\n        <script type="text/javascript">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name="paf_template" content="" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name="ncbi_db" content="pmc" /><meta name="ncbi_pdid" content="article" /><meta name="ncbi_acc" content="" /><meta name="ncbi_domain" content="plosone" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/articles/PMC2440807/" /><meta name="ncbi_app" content="pmc" />\n        <!-- Logger end -->\n        \n        <title>Oct-4 Expression Maintained Cancer Stem-Like Properties in Lung Cancer-Derived CD133-Positive Cells</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440807/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="PLoS ONE" /><meta name="citation_title" content="Oct-4 Expression Maintained Cancer Stem-Like Properties in Lung Cancer-Derived CD133-Positive Cells" /><meta name="citation_authors" content="Yu-Chih Chen, Han-Shui Hsu, Yi-Wei Chen, Tung-Hu Tsai, Chorng-Kuang How, Chien-Ying Wang, Shih-Chieh Hung, Yuh-Lih Chang, Ming-Long Tsai, Yi-Yen Lee, Hung-Hai Ku, Shih-Hwa Chiou" /><meta name="citation_date" content="2008" /><meta name="citation_issue" content="7" /><meta name="citation_volume" content="3" /><meta name="citation_doi" content="10.1371/journal.pone.0002637" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2440807/?report=abstract" /><meta name="citation_pmid" content="18612434" /><meta name="DC.Title" content="Oct-4 Expression Maintained Cancer Stem-Like Properties in Lung Cancer-Derived CD133-Positive Cells" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Public Library of Science" /><meta name="DC.Contributor" content="Yu-Chih Chen" /><meta name="DC.Contributor" content="Han-Shui Hsu" /><meta name="DC.Contributor" content="Yi-Wei Chen" /><meta name="DC.Contributor" content="Tung-Hu Tsai" /><meta name="DC.Contributor" content="Chorng-Kuang How" /><meta name="DC.Contributor" content="Chien-Ying Wang" /><meta name="DC.Contributor" content="Shih-Chieh Hung" /><meta name="DC.Contributor" content="Yuh-Lih Chang" /><meta name="DC.Contributor" content="Ming-Long Tsai" /><meta name="DC.Contributor" content="Yi-Yen Lee" /><meta name="DC.Contributor" content="Hung-Hai Ku" /><meta name="DC.Contributor" content="Shih-Hwa Chiou" /><meta name="DC.Date" content="2008" /><meta name="DC.Identifier" content="10.1371/journal.pone.0002637" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Oct-4 Expression Maintained Cancer Stem-Like Properties in Lung Cancer-Derived CD133-Positive Cells" /><meta property="og:type" content="article" /><meta property="og:description" content="CD133 (prominin-1), a 5-transmembrane glycoprotein, has recently been considered to be an important marker that represents the subset population of cancer stem-like cells. Herein we report the isolation of CD133-positive cells (LC-CD133[+] ) and ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2440807/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" /><meta name="ncbi_feature" content="associated_data" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print" /><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:\'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/\'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-plosone.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name="cited_in_systematic_reviews" content="" /><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC2440807/epub/" /><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC2440807/pdf/pone.0002637.pdf" />\n\n        <!-- Page meta end -->\n    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="8A1BFDA3E99AA9510000000005720570.m_8" />\n<meta name=\'referrer\' content=\'origin-when-cross-origin\'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print" /></head>\n    <body class="article">\n        <div class="grid">\n            <div class="col twelve_col nomargin shadow">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class="sysmessages">\n                    <noscript>\n\t<p class="nojs">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class="wrap">\n                    <div class="page">\n                        <div class="top">\n                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main\n                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to\n                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>\n                            <div class="header">\n    <div class="res_logo">\n  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>\n  <div class="NLMLogo">\n    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>\n    <br />\n    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>\n  </div>\n</div>\n    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:\'pmc-search-autocomplete\',disableUrl:\'NcbiSearchBarAutoComplCtrl\'" autocomplete="off" data-sbconfig="ds:\'no\',pjs:\'no\',afs:\'yes\'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>\n                        <a href="/pmc/advanced/">Advanced</a>\n                    </li><li>\n                        <a href="/pmc/journals/">Journal list</a>\n                    </li><li class="help">\n                        <a target="_blank" href="/books/NBK3825/">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id="Page" label="headcontent"/>-->\n                            \n                        </div>\n                        <div class="content">\n                            <!-- site messages -->\n                            <div class="container">\n    <div id="maincontent" class="content eight_col col">\n        <div class="navlink-box">\n            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="archive"><a class="navlink" href="/pmc/journals/440/">PLoS One</a></li><li class="issue-page"><a class="navlink" href="/pmc/issues/167827/">v.3(7); 2008</a></li><li class="accid">PMC2440807</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class="pmc-page-banner whole_rhythm"><div><img src="/corehtml/pmc/pmcgifs/logo-plosone.gif" alt="Logo of plosone" usemap="#logo-imagemap" /><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" coords="0,0,438,55" alt="PLoS One" title="PLoS One" href="http://www.plosone.org/" ref="reftype=publisher&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="0,56,104,74" alt="View this Article" title="View this Article" href="//dx.doi.org/10.1371/journal.pone.0002637" ref="reftype=publisher&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Content%20Provider%7CArticle%7CFullText" target="pmc_ext" /><area shape="rect" coords="106,56,202,74" alt="Submit to PLoS" title="Submit to PLoS" href="http://www.plosone.org/static/checklist.action" ref="reftype=publisher&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="204,56,302,74" alt="Get E-mail Alerts" title="Get E-mail Alerts" href="http://journals.plos.org/alerts" ref="reftype=publisher&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="304,56,374,74" alt="Contact Us" title="Contact Us" href="http://www.plosone.org/static/contact.action" ref="reftype=publisher&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /><area shape="rect" coords="440,0,500,55" alt="Public Library of Science (PLoS)" title="Public Library of Science (PLoS)" href="http://www.plos.org/" ref="reftype=publisher&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A" target="pmc_ext" /></map></div> </div>\n        \n        <!--component id=\'MainPortlet\' label=\'search-reference\'/-->\n        \n        <!-- Book content -->\n        <div class="">\n            \n        \n            \n            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [\'h2\'], headingExclude: \':hidden\'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span id="pmcmata">PLoS One</span>. 2008; 3(7): e2637. </span></div><div><span class="fm-vol-iss-date">Published online 2008 Jul 9. </span>  <span class="doi">doi:\xc2\xa0<a href="//dx.doi.org/10.1371%2Fjournal.pone.0002637" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1371/journal.pone.0002637</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2440807</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/18612434">18612434</a></div></div></div></div><h1 class="content-title">Oct-4 Expression Maintained Cancer Stem-Like Properties in Lung Cancer-Derived CD133-Positive Cells</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Chen%20YC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434" class="affpopup" co-rid="_co_idm139700235626160" co-class="co-affbox">Yu-Chih Chen</a>,<sup>#</sup><sup>\n1\n</sup> <a href="/pubmed/?term=Hsu%20HS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434" class="affpopup" co-rid="_co_idm139700157878464" co-class="co-affbox">Han-Shui Hsu</a>,<sup>#</sup><sup>\n1\n,</sup><sup>\n3\n,</sup><sup>\n5\n</sup> <a href="/pubmed/?term=Chen%20YW%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434" class="affpopup" co-rid="_co_idm139700160557232" co-class="co-affbox">Yi-Wei Chen</a>,<sup>#</sup><sup>\n1\n,</sup><sup>\n6\n</sup> <a href="/pubmed/?term=Tsai%20TH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434" class="affpopup" co-rid="_co_idm139700160553504" co-class="co-affbox">Tung-Hu Tsai</a>,<sup>\n2\n,</sup><sup>\n9\n</sup> <a href="/pubmed/?term=How%20CK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434" class="affpopup" co-rid="_co_idm139700159121648" co-class="co-affbox">Chorng-Kuang How</a>,<sup>\n1\n,</sup><sup>\n3\n,</sup><sup>\n7\n</sup> <a href="/pubmed/?term=Wang%20CY%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434" class="affpopup" co-rid="_co_idm139700159117040" co-class="co-affbox">Chien-Ying Wang</a>,<sup>\n1\n,</sup><sup>\n7\n</sup> <a href="/pubmed/?term=Hung%20SC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434" class="affpopup" co-rid="_co_idm139700236122832" co-class="co-affbox">Shih-Chieh Hung</a>,<sup>\n1\n,</sup><sup>\n8\n</sup> <a href="/pubmed/?term=Chang%20YL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434" class="affpopup" co-rid="_co_idm139700236119344" co-class="co-affbox">Yuh-Lih Chang</a>,<sup>\n2\n,</sup><sup>\n8\n</sup> <a href="/pubmed/?term=Tsai%20ML%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434" class="affpopup" co-rid="_co_idm139700236115856" co-class="co-affbox">Ming-Long Tsai</a>,<sup>\n8\n</sup> <a href="/pubmed/?term=Lee%20YY%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434" class="affpopup" co-rid="_co_idm139700233443680" co-class="co-affbox">Yi-Yen Lee</a>,<sup>\n1\n,</sup><sup>\n9\n</sup> <a href="/pubmed/?term=Ku%20HH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434" class="affpopup" co-rid="_co_idm139700233440192" co-class="co-affbox">Hung-Hai Ku</a>,<sup>\n4\n,</sup><sup>\n9\n,</sup><sup>\n&#x0002a;\n</sup> and  <a href="/pubmed/?term=Chiou%20SH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434" class="affpopup" co-rid="_co_idm139700233435584" co-class="co-affbox">Shih-Hwa Chiou</a><sup>\n1\n,</sup><sup>\n8\n,</sup><sup>\n&#x0002a;\n</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139700235626160"><h3 class="no_margin">Yu-Chih Chen</h3><p>  <sup>1</sup>  Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan,   </p><div>Find articles by <a href="/pubmed/?term=Chen%20YC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434">Yu-Chih Chen</a></div></div><div id="_co_idm139700157878464"><h3 class="no_margin">Han-Shui Hsu</h3><p>  <sup>1</sup>  Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan,   </p><p>  <sup>3</sup>  Institute of Emergency and Critical Care Medicine, National Yang-Ming University, Taipei, Taiwan,   </p><p>  <sup>5</sup>  Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan,   </p><div>Find articles by <a href="/pubmed/?term=Hsu%20HS%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434">Han-Shui Hsu</a></div></div><div id="_co_idm139700160557232"><h3 class="no_margin">Yi-Wei Chen</h3><p>  <sup>1</sup>  Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan,   </p><p>  <sup>6</sup>  Cancer Center, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan,   </p><div>Find articles by <a href="/pubmed/?term=Chen%20YW%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434">Yi-Wei Chen</a></div></div><div id="_co_idm139700160553504"><h3 class="no_margin">Tung-Hu Tsai</h3><p>  <sup>2</sup>  Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan,   </p><p>  <sup>9</sup>  Department of Medical Research and Education, Taipei City Hospital, Taipei, Taiwan,   </p><div>Find articles by <a href="/pubmed/?term=Tsai%20TH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434">Tung-Hu Tsai</a></div></div><div id="_co_idm139700159121648"><h3 class="no_margin">Chorng-Kuang How</h3><p>  <sup>1</sup>  Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan,   </p><p>  <sup>3</sup>  Institute of Emergency and Critical Care Medicine, National Yang-Ming University, Taipei, Taiwan,   </p><p>  <sup>7</sup>  Department of Emergency, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan,   </p><div>Find articles by <a href="/pubmed/?term=How%20CK%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434">Chorng-Kuang How</a></div></div><div id="_co_idm139700159117040"><h3 class="no_margin">Chien-Ying Wang</h3><p>  <sup>1</sup>  Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan,   </p><p>  <sup>7</sup>  Department of Emergency, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan,   </p><div>Find articles by <a href="/pubmed/?term=Wang%20CY%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434">Chien-Ying Wang</a></div></div><div id="_co_idm139700236122832"><h3 class="no_margin">Shih-Chieh Hung</h3><p>  <sup>1</sup>  Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan,   </p><p>  <sup>8</sup>  Department of Medical Research and Education, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan,   </p><div>Find articles by <a href="/pubmed/?term=Hung%20SC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434">Shih-Chieh Hung</a></div></div><div id="_co_idm139700236119344"><h3 class="no_margin">Yuh-Lih Chang</h3><p>  <sup>2</sup>  Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan,   </p><p>  <sup>8</sup>  Department of Medical Research and Education, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan,   </p><div>Find articles by <a href="/pubmed/?term=Chang%20YL%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434">Yuh-Lih Chang</a></div></div><div id="_co_idm139700236115856"><h3 class="no_margin">Ming-Long Tsai</h3><p>  <sup>8</sup>  Department of Medical Research and Education, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan,   </p><div>Find articles by <a href="/pubmed/?term=Tsai%20ML%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434">Ming-Long Tsai</a></div></div><div id="_co_idm139700233443680"><h3 class="no_margin">Yi-Yen Lee</h3><p>  <sup>1</sup>  Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan,   </p><p>  <sup>9</sup>  Department of Medical Research and Education, Taipei City Hospital, Taipei, Taiwan,   </p><div>Find articles by <a href="/pubmed/?term=Lee%20YY%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434">Yi-Yen Lee</a></div></div><div id="_co_idm139700233440192"><h3 class="no_margin">Hung-Hai Ku</h3><p>  <sup>4</sup>  Institute of Anatomy and Cell Biology, National Yang-Ming University, Taipei, Taiwan,   </p><p>  <sup>9</sup>  Department of Medical Research and Education, Taipei City Hospital, Taipei, Taiwan,   </p><div>Find articles by <a href="/pubmed/?term=Ku%20HH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434">Hung-Hai Ku</a></div></div><div id="_co_idm139700233435584"><h3 class="no_margin">Shih-Hwa Chiou</h3><p>  <sup>1</sup>  Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan,   </p><p>  <sup>8</sup>  Department of Medical Research and Education, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan,   </p><div>Find articles by <a href="/pubmed/?term=Chiou%20SH%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=18612434">Shih-Hwa Chiou</a></div></div></div></div><div class="contrib-group half_rhythm fm-editor">Ming You, <span class="fm-role">Editor</span><sup></sup></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm139700234279872_ai idm139700235626288_ai idm139700161854368_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139700234279872_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139700234279872_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm139700234279872_ai" style="display:none"><div class="fm-affl" lang="en" id="aff1">  <sup>1</sup>  Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan,   </div><div class="fm-affl" lang="en" id="aff2">  <sup>2</sup>  Institute of Traditional Medicine, National Yang-Ming University, Taipei, Taiwan,   </div><div class="fm-affl" lang="en" id="aff3">  <sup>3</sup>  Institute of Emergency and Critical Care Medicine, National Yang-Ming University, Taipei, Taiwan,   </div><div class="fm-affl" lang="en" id="aff4">  <sup>4</sup>  Institute of Anatomy and Cell Biology, National Yang-Ming University, Taipei, Taiwan,   </div><div class="fm-affl" lang="en" id="aff5">  <sup>5</sup>  Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan,   </div><div class="fm-affl" lang="en" id="aff6">  <sup>6</sup>  Cancer Center, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan,   </div><div class="fm-affl" lang="en" id="aff7">  <sup>7</sup>  Department of Emergency, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan,   </div><div class="fm-affl" lang="en" id="aff8">  <sup>8</sup>  Department of Medical Research and Education, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan,   </div><div class="fm-affl" lang="en" id="aff9">  <sup>9</sup>  Department of Medical Research and Education, Taipei City Hospital, Taipei, Taiwan,   </div><div class="fm-affl" lang="en" id="edit1">Washington University, United States of America</div><div><sup>#</sup>Contributed equally.</div><div id="cor1">&#x0002a; E-mail: <a href="mailto:dev@null" data-email="wt.ude.my@ukhh" class="oemail">wt.ude.my@ukhh</a> (H-HK); <a href="mailto:dev@null" data-email="wt.vog.epthgv@uoihchs" class="oemail">wt.vog.epthgv@uoihchs</a> (S-HC)</div><div><p id="__p1" class="p p-first-last">Conceived and designed the experiments: SHC YCC HSH YWC THT SCH HHK. Performed the experiments: SHC YCC HSH YWC CKH MLT. Analyzed the data: SHC YCC HSH YWC THT CYW SCH HHK. Contributed reagents/materials/analysis tools: SHC YCC HSH YWC THT CKH CYW SCH YLC YYL HHK. Wrote the paper: SHC.</p></div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm139700234279872_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2008 Mar 17; Accepted 2008 Jun 8.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm139700234279872_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> Chen et al.</div><div class="license half_rhythm">This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC2440807/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="ass-data" class="tsec fm-sec whole_rhythm" data-section="Featured_PMC_Datacitation"><h2>Associated Data</h2><dl data-count="2" class="box-data-suppmats whole_rhythm no_bottom_margin"><dt><a href="#" rid="data-suppmats" data-ga-action="click_feat_toggler" data-ga-label="Supplementary Materials" class="pmctoggle">Supplementary Materials</a></dt><dd id="data-suppmats" style="display: none;"><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Table S1: </strong>(0.05 MB DOC)</div><div><a href="/pmc/articles/PMC2440807/bin/pone.0002637.s001.doc" data-ga-action="click_feat_suppl">pone.0002637.s001.doc</a><span style="color:gray"> (46K)</span></div><div class="small guid">GUID:\xc2\xa0C2581C46-522D-443C-8D71-37FB93DB4B37</div></div><div class="half_rhythm"><div class="caption half_rhythm no_bottom_margin"><strong>Figure S1: </strong>Correlation of Oct-4 expression levels and the clinical grading and survival rate in the patients with lung cancers. (A) Detection of Oct-4 expression in 78 NSCLC lung cancer patients with different stages by using immunohistochemistry (IHC). Black arrows: positive signals for Oct-4 by IHC. Bar: 50 um. (B) Oct-4 was detected in the almost high grades (III &#x00026; IV) of lung cancer tissues, and significantly expressed the higher intensity of Oct-4-positive signals in grade III &#x00026; IV (high grade) than those in grade I &#x00026; II (low grade) lung cancers patients (p&#x0003c;0.01). (C) Kaplan-Meier analysis of overall survival in 78 lung cancer patients with or without Oct-4 expression.<p>(7.61 MB TIF)</p></div><div><a href="/pmc/articles/PMC2440807/bin/pone.0002637.s002.tif" data-ga-action="click_feat_suppl">pone.0002637.s002.tif</a><span style="color:gray"> (7.2M)</span></div><div class="small guid">GUID:\xc2\xa0073B7157-8ACE-418E-B044-A42CE52BC2FA</div></div></dd></dl></div><div id="idm139700235534672" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139700235534672title">Abstract</h2><!--article-meta--><div><p id="__p2" class="p p-first-last">CD133 (prominin-1), a 5-transmembrane glycoprotein, has recently been considered to be an important marker that represents the subset population of cancer stem-like cells. Herein we report the isolation of CD133-positive cells (LC-CD133<sup>&#x0002b;</sup>) and CD133-negative cells (LC-CD133<sup>&#x02212;</sup>) from tissue samples of ten patients with non-small cell lung cancer (LC) and five LC cell lines. LC-CD133<sup>&#x0002b;</sup> displayed higher Oct-4 expressions with the ability to self-renew and may represent a reservoir with proliferative potential for generating lung cancer cells. Furthermore, LC-CD133<sup>&#x0002b;</sup>, unlike LC-CD133<sup>&#x02212;</sup>, highly co-expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e., cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy. The treatment of Oct-4 siRNA with lentiviral vector can specifically block the capability of LC-CD133<sup>&#x0002b;</sup> to form spheres and can further facilitate LC-CD133<sup>&#x0002b;</sup> to differentiate into LC-CD133<sup>&#x02212;</sup>. In addition, knock-down of Oct-4 expression in LC-CD133<sup>&#x0002b;</sup> can significantly inhibit the abilities of tumor invasion and colony formation, and increase apoptotic activities of caspase 3 and poly (ADP-ribose) polymerase (PARP). Finally, <em>in vitro</em> and <em>in vivo</em> studies further confirm that the treatment effect of chemoradiotherapy for LC-CD133<sup>&#x0002b;</sup> can be improved by the treatment of Oct-4 siRNA. In conclusion, we demonstrated that Oct-4 expression plays a crucial role in maintaining the self-renewing, cancer stem-like, and chemoradioresistant properties of LC-CD133<sup>&#x0002b;</sup>. Future research is warranted regarding the up-regulated expression of Oct-4 in LC-CD133<sup>&#x0002b;</sup> and malignant lung cancer.</p></div></div><div id="s1" class="tsec sec"><h2 class="head no_bottom_margin" id="s1title">Introduction</h2><p id="__p3" class="p p-first">Lung cancer is one of the leading causes of cancer-related deaths in industrialized countries <a href="#pone.0002637-Spira1" rid="pone.0002637-Spira1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399477">[1]</a>, <a href="#pone.0002637-Hsu1" rid="pone.0002637-Hsu1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399454">[2]</a>. Radiotherapy and chemotherapy play significant and crucial roles in clinical anti-lung cancer treatment to achieve prolonged patient survival <a href="#pone.0002637-Socinski1" rid="pone.0002637-Socinski1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399473">[3]</a>, <a href="#pone.0002637-Bernstein1" rid="pone.0002637-Bernstein1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399448">[4]</a>. However, a high failure rate and low median survival rate are observed in patients undergoing chemoradiotherapy with recurrent, intractable lung cancer <a href="#pone.0002637-Lam1" rid="pone.0002637-Lam1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399453">[5]</a>. To improve the patient survival rate, investigation to elucidate the mechanism of tumorigenesis of lung cancer is needed <a href="#pone.0002637-Lam1" rid="pone.0002637-Lam1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399471">[5]</a>. Recent data have demonstrated that tumors contain a small subpopulation of cells, i.e., cancer stem-like cells (CSCs) or cancer-initiating cells (CICs), which exhibit a self-renewing capacity and are responsible for tumor maintenance and metastasis <a href="#pone.0002637-Jordan1" rid="pone.0002637-Jordan1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399455">[6]</a>. Stem cells have been isolated by their ability to efflux Hoechst 33342 dye and are referred to as the &#x0201c;side population (SP)&#x0201d; <a href="#pone.0002637-Goodell1" rid="pone.0002637-Goodell1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399475">[7]</a>. Ho and colleagues isolated and characterized SP cells from six human lung cancer cell lines and showed that an elevated expression of ABCG2 as well as other ATP-binding cassette transporters were positively correlated with resistance to multiple chemotherapeutic drugs <a href="#pone.0002637-Ho1" rid="pone.0002637-Ho1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399464">[8]</a>. In addition, Gutova and colleagues have purified uPAR-positive CSCs from three lung cancer cell lines. These uPAR-positive cells co-expressed with CD44 and MDR1, and had the ability to promote advanced malignancy and chemoresistance <a href="#pone.0002637-Gutova1" rid="pone.0002637-Gutova1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399472">[9]</a>.</p><p id="__p4">CD133 (prominin-1), a 5-transmembrane glycoprotein, was first recognized in CD34<sup>&#x0002b;</sup> progenitor populations from adult blood, bone marrow, and fetal liver cells <a href="#pone.0002637-Yin1" rid="pone.0002637-Yin1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399476">[10]</a>. Recently, CD133 has been considered an important marker to represent the subset population of CSCs in leukemia, brain tumors, retinoblastoma, renal tumors, pancreatic tumors, colon carcinoma, prostate carcinoma, and hepatocellular carcinoma <a href="#pone.0002637-Collins1" rid="pone.0002637-Collins1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399467">[11]</a>&#x02013;<a href="#pone.0002637-Bruno1" rid="pone.0002637-Bruno1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399463">[19]</a>. Based on immunohistochemical findings, Hilbe and colleagues suggested that CD133-positive (CD133<sup>&#x0002b;</sup>) progenitor cells play a role in the development of tumor vasculature in patients with non-small-cell lung cancer (NSCLC) <a href="#pone.0002637-Hilbe1" rid="pone.0002637-Hilbe1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399456">[20]</a>. More recently, a well-designed study by Eramo and colleagues showed that lung cancer contains a population of CD133<sup>&#x0002b;</sup> CSCs able to self-renew and generate an unlimited progeny of non-tumorigenic cells. These CD133<sup>&#x0002b;</sup> cells are also resistant to conventional chemotherapy <a href="#pone.0002637-Eramo1" rid="pone.0002637-Eramo1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399462">[21]</a>. However, the gene regulation mechanisms in maintaining the self-renewal and drug-resistant properties in putative cancer stem-like cells of lung tumors are still unclear.</p><p id="__p5">Oct-4, a member of the family of POU-domain transcription factors, is expressed in pluripotent embryonic stem (ES) and germ cells <a href="#pone.0002637-Rosner1" rid="pone.0002637-Rosner1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399470">[22]</a>&#x02013;<a href="#pone.0002637-Burdon1" rid="pone.0002637-Burdon1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399447">[23]</a>. Oct-4 mRNA is normally found in totipotent and pluripotent stem cells of pregastrulation embryos <a href="#pone.0002637-Boiani1" rid="pone.0002637-Boiani1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399458">[24]</a>. Knocking out the <em>Oct-4</em> gene in mice causes early lethality due to the lack of ICM formation, indicating that Oct-4 has a critical function for self-renewal of ES cells <a href="#pone.0002637-Nichols1" rid="pone.0002637-Nichols1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399441">[25]</a>. Oct-4 activates transcription via octamer motifs, and Oct-4 binding sites have been found in various genes, including <em>fgf 4</em> (fibroblast growth factor 4) and <em>pdgf</em>&#x003b1;<em>r</em> (platelet-derived growth factor &#x003b1; receptor) <a href="#pone.0002637-Lamb1" rid="pone.0002637-Lamb1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399440">[26]</a>, <a href="#pone.0002637-Kraft1" rid="pone.0002637-Kraft1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399449">[27]</a>. This suggests that Oct-4 functions as a master switch during differentiation by regulating the pluripotent potentials of the stem cell, and Oct-4 plays a pivotal role in mammalian development <a href="#pone.0002637-Boiani1" rid="pone.0002637-Boiani1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399436">[24]</a>, <a href="#pone.0002637-Nichols1" rid="pone.0002637-Nichols1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399481">[25]</a>.</p><p id="__p6" class="p p-last">In this study, the CD133-positive cells (LC-CD133<sup>&#x0002b;</sup>) and CD133-negative cells (LC-CD133<sup>&#x02212;</sup>) were isolated from tissue samples of lung cancer (LC) patients and LC cell lines. These LC-CD133<sup>&#x0002b;</sup> cells possessed both the characteristics of stem-like cells and malignant tumors. Our data further demonstrated that Oct-4 expression in LC-CD133<sup>&#x0002b;</sup> is involved in tumor malignancy of lung cancers and exhibits refractory properties for chemoradiotherapy in cancer stem-like cells. These results suggested that the expression of Oct-4 plays a crucial role in maintaining cancer stem-like and chemoradioresistant properties in lung cancer-derived CD133<sup>&#x0002b;</sup> cells.</p></div><div id="s2" class="tsec sec"><h2 class="head no_bottom_margin" id="s2title">Materials and Methods</h2><div id="s2a" class="sec sec-first"><h3 id="s2atitle">Isolation of CD133<sup>&#x0002b;</sup> Cell Subset</h3><p id="__p7" class="p p-first">This research followed the tenets of the Declaration of Helsinki and all samples were obtained after patients provided informed consent. The study was approved by the Institutional Ethics Committee/Institutional Review Board of Taipei Veterans General Hospital. The dissociated cells from the samples of non-small cell lung cancer patients (<a href="/pmc/articles/PMC2440807/table/pone-0002637-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0002637-t001" rid-ob="ob-pone-0002637-t001" co-legend-rid=""><span>Table 1</span></a>) and the lung cancer (LC) cell lines were labeled with 1 mL CD133/l micromagnetic beads per 1 million cells using the CD133 cell isolation kit (Miltenyi Biotech, Auburn, CA). CD133<sup>&#x0002b;</sup> cells were cultured in a medium consisting of serum-free DMEM/F12 (Gibco-BRL, Gaithersburg, MD), N2 supplement (R&#x00026;D Systems Inc., Minneapolis), 10 ng/ml human recombinant bFGF (R&#x00026;D Systems) and 10 ng/ml EGF (R&#x00026;D Systems) <a href="#pone.0002637-Chiou1" rid="pone.0002637-Chiou1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399445">[28]</a>.</p><!--table ft1--><!--table-wrap mode="anchored" t5--><div class="table-wrap table anchored whole_rhythm" id="pone-0002637-t001"><h3>Table 1</h3><!--caption a7--><div class="caption"><!--caption a8--><strong>The tumor formation abilities of CD133<sup>&#x0002b;</sup> and CD133<sup>&#x02212;</sup> in NSCLC description and tumorigenic characteristics of CD133<sup>&#x0002b;</sup>\n</strong></div><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139700233329008" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table"><thead><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td colspan="2" align="left" rowspan="1">Tumor formation</td></tr><tr><td align="left" rowspan="1" colspan="1">No.</td><td align="left" rowspan="1" colspan="1">Type</td><td align="left" rowspan="1" colspan="1">Staging/TNM</td><td align="left" rowspan="1" colspan="1">CD133&#x0002b;(&#x00025;)</td><td align="left" rowspan="1" colspan="1">SF</td><td align="left" rowspan="1" colspan="1">CD133&#x0002b;</td><td align="left" rowspan="1" colspan="1">CD133&#x02212;</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">\n<strong>AC</strong>\n</td><td align="left" rowspan="1" colspan="1">IIIB pT4pN3pMX</td><td align="left" rowspan="1" colspan="1">5.9</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">10,000(3/3)</td><td align="left" rowspan="1" colspan="1">10,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">3,000(3/3)</td><td align="left" rowspan="1" colspan="1">3,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1,000(3/3)</td><td align="left" rowspan="1" colspan="1">1,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">\n<strong>AC</strong>\n</td><td align="left" rowspan="1" colspan="1">IIIA pT2pN2pMX</td><td align="left" rowspan="1" colspan="1">2.6</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">10,000(3/3)</td><td align="left" rowspan="1" colspan="1">10,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">3,000(3/3)</td><td align="left" rowspan="1" colspan="1">3,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1,000(3/3)</td><td align="left" rowspan="1" colspan="1">1,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">\n<strong>AC</strong>\n</td><td align="left" rowspan="1" colspan="1">IIA pT1pN1pMX</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">10,000(3/3)</td><td align="left" rowspan="1" colspan="1">10,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">3,000(3/3)</td><td align="left" rowspan="1" colspan="1">3,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1,000(1/3)</td><td align="left" rowspan="1" colspan="1">1,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">\n<strong>AC</strong>\n</td><td align="left" rowspan="1" colspan="1">IIB pT3pN0pMX</td><td align="left" rowspan="1" colspan="1">1.4</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">10,000(3/3)</td><td align="left" rowspan="1" colspan="1">10,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">3,000(3/3)</td><td align="left" rowspan="1" colspan="1">3,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1,000(3/3)</td><td align="left" rowspan="1" colspan="1">1,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">\n<strong>AC</strong>\n</td><td align="left" rowspan="1" colspan="1">IIB pT2pN1pMX</td><td align="left" rowspan="1" colspan="1">0.5</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">10,000(3/3)</td><td align="left" rowspan="1" colspan="1">10,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">3,000(2/3)</td><td align="left" rowspan="1" colspan="1">3,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1,000(1/3)</td><td align="left" rowspan="1" colspan="1">1,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">\n<strong>AC</strong>\n</td><td align="left" rowspan="1" colspan="1">IIIA pT3pN1pMX</td><td align="left" rowspan="1" colspan="1">0.7</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">10,000(3/3)</td><td align="left" rowspan="1" colspan="1">10,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">3,000(3/3)</td><td align="left" rowspan="1" colspan="1">3,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1,000(1/3)</td><td align="left" rowspan="1" colspan="1">1,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">\n<strong>AC</strong>\n</td><td align="left" rowspan="1" colspan="1">IIIB pT3pN3pMX</td><td align="left" rowspan="1" colspan="1">3.7</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">10,000(3/3)</td><td align="left" rowspan="1" colspan="1">10,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">3,000(3/3)</td><td align="left" rowspan="1" colspan="1">3,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1,000(3/3)</td><td align="left" rowspan="1" colspan="1">1,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">\n<strong>SCC</strong>\n</td><td align="left" rowspan="1" colspan="1">IA pT1pN0pMX</td><td align="left" rowspan="1" colspan="1">0.3</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">10,000(3/3)</td><td align="left" rowspan="1" colspan="1">10,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">3,000(2/3)</td><td align="left" rowspan="1" colspan="1">3,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1,000(0/3)</td><td align="left" rowspan="1" colspan="1">1,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">\n<strong>SCC</strong>\n</td><td align="left" rowspan="1" colspan="1">IIIA pT3pN2pMX</td><td align="left" rowspan="1" colspan="1">2.3</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">10,000(3/3)</td><td align="left" rowspan="1" colspan="1">10,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">3,000(3/3)</td><td align="left" rowspan="1" colspan="1">3,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1,000(2/3)</td><td align="left" rowspan="1" colspan="1">1,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">\n<strong>SCC</strong>\n</td><td align="left" rowspan="1" colspan="1">IIIA pT2pN2pMX</td><td align="left" rowspan="1" colspan="1">1.1</td><td align="left" rowspan="1" colspan="1">Yes</td><td align="left" rowspan="1" colspan="1">10,000(3/3)</td><td align="left" rowspan="1" colspan="1">10,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">3,000(3/3)</td><td align="left" rowspan="1" colspan="1">3,000(0/3)</td></tr><tr><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1">1,000(3/3)</td><td align="left" rowspan="1" colspan="1">1,000(0/3)</td></tr></tbody></table></div><div id="largeobj_idm139700233329008" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2440807/table/pone-0002637-t001/?report=objectonly">Open in a separate window</a></div><div class="tblwrap-foot"><div id="nt101"><sup></sup>CD133<sup>&#x0002b;</sup> and CD133<sup>&#x02212;</sup> cells were injected into the tail vein of SCID mice, respectively. NSCLC: non-small cell lung cancer. SF: sphere formation. AC: adenocarcinoma. SCC: squamous cell carcinoma. Positive response (Positivity): the tumor formation in the lung tissues of SCID mice. Sphere Formation: Under serum-free medium with bFGF &#x00026; EGF culture for 4 weeks.</div></div></div></div><div id="s2b" class="sec"><h3 id="s2btitle">Cell Viability Determined by Colorimetric Assay</h3><p id="__p9" class="p p-first-last">The isolated CD133<sup>&#x0002b;</sup> and CD133<sup>&#x02212;</sup> cells were cultured in a 96-well cell culture cluster (Corning Costar, Acton, MA) at a density of 3&#x000d7;10<sup>3</sup> cells/well with 100 &#x000b5;l culture medium. At specific time points during cultivation, the medium was discarded and replaced with an equal volume (100 &#x000b5;l) of fresh medium containing 0.2 mg/ml of 3- (4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS, Promega, Madison, WI) and 0.038 mg/ml of phenazine methosulfate (PMS; Promega) and incubated for additional 1.5 hours in 37&#x000b0;C 5&#x00025; CO<sub>2</sub>. Cell viability proportionate to optical density (OD) was measured by colorimetric assay in terms of mitochondria activity to convert tetrazolium salt into a colored soluble formazan product in the medium. The OD values were measured at the wavelength of 490 nm with a 1420 multilabel counter VICTOR from Wallac (PerkinElmer Wallac, Turku, Finland).</p></div><div id="s2c" class="sec"><h3 id="s2ctitle">Real-time Reverse Transcription-polymerase Chain Reaction (RT-PCR)</h3><p id="__p10" class="p p-first-last">For real-time RT-PCR analysis, the total RNA of cells was extracted by using the RNA<sub>easy</sub> kit (Qiagen, Valencia, CA). Briefly, the total RNA (1 &#x000b5;g) of each sample was reversely transcribed in 20 &#x000b5;L using 0.5 &#x000b5;g of oligo dT and 200 U Superscript II RT (Invitrogen, Carlsbad, CA). The amplification was carried out in a total volume of 20 &#x000b5;l containing 0.5 &#x000b5;M of each primer, 4 mM MgCl<sub>2</sub>, 2 &#x000b5;l LightCycler FastStart DNA Master SYBR green I (Roche Diagnostics, Pleasanton, CA) and 2 &#x000b5;l of 1&#x02236;10 diluted cDNA. The quantification of the unknown samples was performed by LightCycler Relative Quantification Software, version 3.3 (Roche Diagnostics). In each experiment, the GAPDH housekeeping gene was amplified as a reference standard. GAPDH primers were designed: GAPDH(f): <em class="gene">GCCAAAAGGGTCATCATC</em> (nt 448&#x02013;465, GenBank accession no. <a id="__tag_805237589" class="tag_hotlink" href="/nuccore/NM_002046" ref="/nuccore/NM_002046"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"NM_002046","term_id":"1519316078","term_text":"NM_002046"}}</span>NM_002046</a>), GAPDH(r): <em class="gene">ATGACCTTGCCCACA GCCTT</em> (nt 745&#x02013;765), Oct-4a(f): <em class="gene">CGCAAGCCCTCATTTCAC</em> (nt 5&#x02013;22, GenBank accession no. <a id="__tag_805237587" class="tag_hotlink" href="/nuccore/NM_002701" ref="/nuccore/NM_002701"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"NM_002701","term_id":"1519314212","term_text":"NM_002701"}}</span>NM_002701</a>), Oct-4a(r): <em class="gene">CATCACCTCCACCACCTG</em> (nt 98&#x02013;115, GenBank accession no. <a id="__tag_805237586" class="tag_hotlink" href="/nuccore/NM_002701" ref="/nuccore/NM_002701"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"NM_002701","term_id":"1519314212","term_text":"NM_002701"}}</span>NM_002701</a>). PCR reactions were prepared in duplicate and heated to 95&#x000b0;C for 10 minutes followed by 40 cycles of denaturation at 95&#x000b0;C for 10 seconds, annealing at 55&#x000b0;C for 5 seconds, and extension at 72&#x000b0;C for 20 seconds. All PCR reactions were performed in duplicate. Standard curves (cycle threshold values versus template concentration) were prepared for each target gene and for the endogenous reference (GAPDH) in each sample.</p></div><div id="s2d" class="sec"><h3 id="s2dtitle">Immunofluorescence Staining for Stem Cell Markers</h3><p id="__p11" class="p p-first-last">An avidin-biotin complex method was used for the immunofluorescence staining in the differentiated spheroid and neuronal-like cell. In brief, cells were plated onto poly-L-ornithine-coated glass coverslips and fixed with 4&#x00025; paraformaldehyde for 15 to 20 minutes at room temperature, and then were washed twice (10 minutes each) with 1&#x000d7; PBS. Cells were permeabilized with 0.1&#x00025; Triton X-100/PBS for 10 minutes at room temperature, and then twice (10 minutes each) with 1&#x000d7; PBS. The cells were then blocked with blocking solution for 30 minutes and were incubated with primary antibodies (Oct-4, Chemicon, Temecula, CA) for 1 hour at room temperature. We then washed the cells three times (10 minutes each) with 1&#x000d7; PBS. Immunoreactive signals were detected with a mixture of biotinylated rabbit antimouse IgG and Fluorsave (Calbiochem, San Diego, CA). Cells were further probed with fluorescein isothiocyanate (FITC)-tagged secondary antibodies. Fluorescence images were visualized with a fluorescence microscope. To quantitatively analyze the fluorescence intensity, we recorded images with an inverted fluorescence microscope equipped with a CCD camera. The percentage of signal fluorescence per photographed field was analyzed by image processing software (Image Pro-Plus, MediaCybernetics, Inc., Silver Spring, MD).</p></div><div id="s2e" class="sec"><h3 id="s2etitle">FACS Analysis</h3><p id="__p12" class="p p-first-last">For cell surface marker identification, a single cell suspension of sixth- to eighth-passage cells from trypsinized spheres was stained with anti-CD133, CD117 (c-Kit), or ABCG2 and secondary fluorescein (FITC)-or phycoerythrin (PE)-coupled antibodies (Dako, Carpinteria). Cells were fixed with 2&#x00025; paraformaldehyde and were analyzed with a BD FACSCalibur apparatus (Becton, Dickinson and Company, Franklin Lakes, NJ).</p></div><div id="s2f" class="sec"><h3 id="s2ftitle">Radiation Treatment for Cell Viability Analysis</h3><p id="__p13" class="p p-first-last">The gamma radiation (ionizing irradiation; IR) was delivered by a Theratronic cobalt unit T-1000 (Theratronic International, Inc., Ottawa, Canada) at a dose rate of 1.1Gy/min (SSD&#x0200a;=&#x0200a;57.5cm). To evaluate the cell proliferation rate we seeded cells on 24-well plates at a density of 2&#x000d7;10<sup>4</sup> cells/well. Cells were seeded 24 hours after IR and then they were analyzed by methyle thiazol tetrazolium assay (MTT assay, Sigma-Aldrich, St. Louis, MN). The amount of MTT formazon product was determined by using a microplate reader and the absorbance was measured at 560 nm (SpectraMax 250, Molecular Devices, Sunnyvale, CA).</p></div><div id="s2g" class="sec"><h3 id="s2gtitle">Chemotherapeutic Agents</h3><p id="__p14" class="p p-first-last">Cisplatin, etoposide (VP16), and paclitaxel were obtained from Sigma-Aldrich and were dissolved in DMSO (Sigma-Aldrich) at 100 mM of stock solution.</p></div><div id="s2h" class="sec"><h3 id="s2htitle">\n<em>In Vitro</em> Cell Invasion Analysis and Soft Agar Colony Assay</h3><p id="__p15" class="p p-first-last">The 24-well plate Transwell system with an 8-&#x000b5;m pore size polycarbonate filter membrane (Corning Costar, Corning, NY) was used. The filter membrane was coated with Matrigel (BD Biosciences, San Diego) diluted with serum-free medium and incubated overnight at 37&#x000b0;C. The cell suspensions were seeded to the upper compartment of the Transwell chamber at the cell density of 1&#x000d7;10<sup>5</sup> in 100 &#x000b5;l serum free medium. After 24 hours, the medium was removed and the filter membrane was fixed with 4&#x00025; formalin for 1 hour. The opposite surface of the filter membrane facing the lower chamber was stained with Hoechst 33342 (Sigma-Aldrich) for 3 minutes and the migrated cells were then visualized under an inverted microscope. The protocol of soft agar colony assay is described as follows. Each well (35 mm) of a six-well culture dish was coated with 2 ml bottom agar mixture (DMEM, 10&#x00025; (v/v) FCS, 0.6&#x00025; (w/v) agar). After the bottom layer solidified, 2 ml top agar-medium mixture (DMEM, 10&#x00025; (v/v) FCS, 0.3&#x00025; (w/v) agar) containing 2&#x000d7;10<sup>4</sup> cells was added, and the dishes were incubated at 37&#x000b0;C for 4 weeks. Plates were stained with 0.5 ml of 0.005&#x00025; crystal violet for 1 hour and then a dissecting microscope was used to count the number of colonies <a href="#pone.0002637-Yang1" rid="pone.0002637-Yang1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399437">[29]</a>.</p></div><div id="s2i" class="sec"><h3 id="s2ititle">Lentiviral-mediated RNAi</h3><p id="__p16" class="p p-first-last">The pLVRNAi vector and pCDH-MCS1-EF1-copGFP vector were purchased from Biosettia Inc. (Biosettia, San Diego, CA). The method of cloning the double-stranded shRNA sequence is described in the manufacturer\'s protocol. The siRNA oligonucleotide <em class="gene">5&#x02032;-CCGGCCCTCACTTCACTGCACTGTACTCGAGTACAGTGC AGTGAAGTGAGGGTTTTT-3&#x02032;</em> targeting human Oct-4 (<a id="__tag_805237588" class="tag_hotlink" href="/nuccore/NM_002701" ref="/nuccore/NM_002701"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"NM_002701","term_id":"1519314212","term_text":"NM_002701"}}</span>NM_002701</a>, nt 1035-1055) was synthesized and cloned into pLVRNAi to generate a lentiviral expression vector. The Oct-4 cDNA was amplified and purified by RT-PCR and cloned into a pCDH-MCS1-EF1-copGFP vector. Lentiviral production was done by transfection of 293T cells using Lipofectamine 2000 (LF2000, Invitrogen). Supernatants were collected 48 hours after transfection and then were filtered; the viral titers were then determined by FACS at 48 hours post-transduction. Subconfluent cells were infected with lentivirus at a multiplicity of infection of 5 in the presence of 8 &#x000ec;g/ml polybrene (Sigma-Aldrich).</p></div><div id="s2j" class="sec"><h3 id="s2jtitle">\n<em>In Vivo</em> Analysis of Tumor Growth and Metastasis</h3><p id="__p17" class="p p-first-last">All procedures involving animals were in accordance with the institutional animal welfare guidelines of Taipei Veterans General Hospital. 1000, 3000, and 10<sup>4</sup> cells were injected into the tail vein of SCID mice and/or nude mice (BALB/c strain) each aged 8 weeks. In vivo GFP imaging was visualized and measured by an illuminating device (LT-9500 Illumatool TLS equipped with excitation illuminating source [470 nm] and filter plate [515 nm]). The tumor size was measured with calipers and the tumor volume was calculated according to the formula (Length&#x000d7;Width<sup>2</sup>)/2. The integrated optical density of green fluorescence intensity was captured and then analyzed by Image Pro-plus software <a href="#pone.0002637-Yang1" rid="pone.0002637-Yang1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399479">[29]</a>.</p></div><div id="s2k" class="sec sec-last"><h3 id="s2ktitle">Statistical Analysis</h3><p id="__p18" class="p p-first-last">Statistical Package of Social Sciences software (version 13.0) (SPSS, Inc., Chicago, IL) was used for statistical analysis. The independent Student\'s <em>t</em>-test or ANOVA was used to compare the continuous variables between groups, whereas the &#x003c7;<sup>2</sup> test was applied for comparison of dichotomous variables. The Kaplan-Meier estimate was used for survival analysis, and the log-rank test was used to compare the cumulative survival durations in different patient groups. The level of statistical significance was set at 0.05 for all tests.</p></div></div><div id="s3" class="tsec sec"><h2 class="head no_bottom_margin" id="s3title">Results</h2><div id="s3a" class="sec sec-first"><h3 id="s3atitle">Isolation and Characterization of Lung Cancer-derived CD133-positive Cells</h3><p id="__p19" class="p p-first">Using the magnetic bead method, we isolated CD133<sup>&#x0002b;</sup> cells (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g001" rid-ob="ob-pone-0002637-g001" co-legend-rid="lgnd_pone-0002637-g001"><span>Fig. 1A</span></a>) from tissue samples of ten non-small cell lung cancer (NSCLC) patients (<a href="/pmc/articles/PMC2440807/table/pone-0002637-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0002637-t001" rid-ob="ob-pone-0002637-t001" co-legend-rid=""><span>Table 1</span></a>) and five lung cancer (LC) cell lines (<a href="#pone.0002637.s001" rid="pone.0002637.s001" class=" supplementary-material">Table S1</a>). The high percentage (97&#x00025;) of CD133<sup>&#x0002b;</sup> (LC-CD133<sup>&#x0002b;</sup>) subset was isolated in the LC tissues and parental LC cell line (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g001" rid-ob="ob-pone-0002637-g001" co-legend-rid="lgnd_pone-0002637-g001"><span>Fig. 1A</span></a>). It has been reported that cancer stem-like cells can be cultured in suspension to generate floating spheroid-like bodies (SB) under serum-free medium with bFGF &#x00026; EGF <a href="#pone.0002637-Lee1" rid="pone.0002637-Lee1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399474">[30]</a>. We found that LC-CD133<sup>&#x0002b;</sup> isolated from these ten patients (<a href="/pmc/articles/PMC2440807/table/pone-0002637-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0002637-t001" rid-ob="ob-pone-0002637-t001" co-legend-rid=""><span>Table 1</span></a>) and five LC cell lines (<a href="#pone.0002637.s001" rid="pone.0002637.s001" class=" supplementary-material">Table S1</a>) can form SB in DF-12 serum-free medium with bFGF and EGF (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g001" rid-ob="ob-pone-0002637-g001" co-legend-rid="lgnd_pone-0002637-g001"><span>Fig. 1B</span></a>; No.1 [PLC] and No.2 [LLC]). Furthermore, the ability to form SB (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g001" rid-ob="ob-pone-0002637-g001" co-legend-rid="lgnd_pone-0002637-g001"><span>Fig. 1C</span></a>) and proliferation rate (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g001" rid-ob="ob-pone-0002637-g001" co-legend-rid="lgnd_pone-0002637-g001"><span>Fig. 1D</span></a>) in LC-CD133<sup>&#x0002b;</sup> were significantly higher than that in LC-CD133<sup>&#x02212;</sup> (p&#x0003c;0.05). In addition, to determine the <em>in vivo</em> tumorigenic activity of LC-CD133<sup>&#x0002b;</sup> and LC-CD133<sup>&#x02212;</sup>, we injected respective amounts of 1000, 3000, and 10<sup>4</sup> cells into the tail veins of SCID mice. The results showed that 10<sup>4</sup> LC-CD133<sup>&#x02212;</sup> did not induce tumor formation but 3,000 LC-CD133<sup>&#x0002b;</sup> from the lung cancer tissues of ten patients and five LC cell lines in xenotransplanted mice can all generate visible tumors 4 weeks after injection (<a href="/pmc/articles/PMC2440807/table/pone-0002637-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0002637-t001" rid-ob="ob-pone-0002637-t001" co-legend-rid=""><span>Table 1</span></a> and <a href="#pone.0002637.s001" rid="pone.0002637.s001" class=" supplementary-material">Table S1</a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="pone-0002637-g001" co-legend-rid="lgnd_pone-0002637-g001"><a href="/pmc/articles/PMC2440807/figure/pone-0002637-g001/" target="figure" rid-figpopup="pone-0002637-g001" rid-ob="ob-pone-0002637-g001"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139700162630496" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2440807_pone.0002637.g001.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is pone.0002637.g001.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2440807/bin/pone.0002637.g001.jpg" /></a></div><div id="largeobj_idm139700162630496" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2440807/figure/pone-0002637-g001/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_pone-0002637-g001"><div><a class="figpopup" href="/pmc/articles/PMC2440807/figure/pone-0002637-g001/" target="figure" rid-figpopup="pone-0002637-g001" rid-ob="ob-pone-0002637-g001">Figure 1</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Isolation and characterization of lung cancer-derived CD133<sup>&#x0002b;</sup> (LC-CD133<sup>&#x0002b;</sup>).</strong><p id="__p20">(A) Using a magnetic bead method, we sorted CD133<sup>&#x0002b;</sup> cells from tissue samples of patients with lung cancer (LC), and characterized them by FACS assay. (B) LC-CD133<sup>&#x0002b;</sup> sorted from two patient with No.1 (PLC-CD133<sup>&#x0002b;</sup>) and No.2 (LLC-CD133<sup>&#x0002b;</sup>) were cultured in bFGF and EGF with DMEM serum-free medium. (C) Evaluation of the formation abilities of spheroid-like bodies (SB) from LC-CD133<sup>&#x0002b;</sup> and LC-CD133<sup>&#x02212;</sup> under serum-free medium with bFGF &#x00026; EGF. (D) The growth curves of LC-CD133<sup>&#x0002b;</sup> and LC-CD133<sup>&#x02212;</sup> were measured by hemocytometer. Bar: 100 &#x000b5;m. Data shown here are the mean&#x000b1;SD of three experiments.</p></div></div></div></div><div id="s3b" class="sec"><h3 id="s3btitle">Increased ABCG2 Expression and Invasive Ability of LC-CD133<sup>&#x0002b;</sup>\n<em>In Vitro</em>\n</h3><p id="__p21" class="p p-first">To characterize our isolated LC-CD133<sup>&#x0002b;</sup>, FACS analysis was used to detect the expression profile of cells surface markers. As shown in <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g002" rid-ob="ob-pone-0002637-g002" co-legend-rid="lgnd_pone-0002637-g002"><span>Figure 2A</span></a>, the majority of isolated LC-CD133<sup>&#x0002b;</sup> were stained with higher expression levels of CD133, CD117 (c-Kit), and ABCG2 compared with LC-CD133<sup>&#x02212;</sup>. This result demonstrated that isolated LC-CD133<sup>&#x0002b;</sup> were almost ABCG2-positive cells (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g002" rid-ob="ob-pone-0002637-g002" co-legend-rid="lgnd_pone-0002637-g002"><span>Fig. 2B</span></a>). To further evaluate the enhancement of tumorigenicity of LC-CD133<sup>&#x0002b;</sup>, we examined <em>in vitro</em> Matrigel-combined Transwell invasion and soft agar colony formation assays. Compared with LC-CD133<sup>&#x02212;</sup>, LC-CD133<sup>&#x0002b;</sup> derived from NSCLC Patients No.1 (PLC) and No. 2 (LLC) showed higher invasion activity through Matrigel Transwell invasion assay (<em>p</em>&#x0003c;0.001; <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g002" rid-ob="ob-pone-0002637-g002" co-legend-rid="lgnd_pone-0002637-g002"><span>Fig. 2C</span></a>). Similarly, the foci formation ability of LC-CD133<sup>&#x0002b;</sup> from PLC (No.1) and LLC (No.2) was enhanced when compared with the LC-CD133<sup>&#x02212;</sup> of those two patients (<em>p</em>&#x0003c;0.001; <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g002" rid-ob="ob-pone-0002637-g002" co-legend-rid="lgnd_pone-0002637-g002"><span>Fig. 2D</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="pone-0002637-g002" co-legend-rid="lgnd_pone-0002637-g002"><a href="/pmc/articles/PMC2440807/figure/pone-0002637-g002/" target="figure" rid-figpopup="pone-0002637-g002" rid-ob="ob-pone-0002637-g002"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139700232952224" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2440807_pone.0002637.g002.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is pone.0002637.g002.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2440807/bin/pone.0002637.g002.jpg" /></a></div><div id="largeobj_idm139700232952224" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2440807/figure/pone-0002637-g002/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_pone-0002637-g002"><div><a class="figpopup" href="/pmc/articles/PMC2440807/figure/pone-0002637-g002/" target="figure" rid-figpopup="pone-0002637-g002" rid-ob="ob-pone-0002637-g002">Figure 2</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Detection of surface markers and the tumorigenicity in LC-CD133<sup>&#x0002b;</sup> and LC-CD133<sup>&#x02212;</sup>\n<em>in vitro</em>.</strong><p id="__p22">(A) and (B) The expression levels of CD133, CD117 (c-Kit), and ABCG2 were analyzed by FACS assay in LC-CD133<sup>&#x0002b;</sup> and LC-CD133<sup>&#x02212;</sup>. The capabilities of (C) the migration/invasion and (D) the tumor foci (soft agar colony) formation in LC-CD133<sup>&#x0002b;</sup> were significantly increased compared with LC-CD133<sup>&#x02212;</sup> (&#x0002a;<em>p</em>&#x0003c;0.001). Data shown here are the mean&#x000b1;SD of three experiments.</p></div></div></div></div><div id="s3c" class="sec"><h3 id="s3ctitle">Increased <em>In Vivo</em> Tumor-restoration and Proliferative Ability in LC-CD133<sup>&#x0002b;</sup>\n</h3><p id="__p23" class="p p-first">We further evaluated the <em>in vivo</em> tumor-restoration and proliferative ability of LC-CD133<sup>&#x0002b;</sup> and LC-CD133<sup>&#x02212;</sup> by xenotransplanted tumorigenicity analysis (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g003" rid-ob="ob-pone-0002637-g003" co-legend-rid="lgnd_pone-0002637-g003"><span>Fig. 3A</span></a>). Four weeks after 10<sup>4</sup> cells were injected into the tail veins of SCID mice, a significant increase in the multiple nodules of tumor formation on lung surface was noted in the LC-CD133<sup>&#x0002b;</sup>-injected group (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g003" rid-ob="ob-pone-0002637-g003" co-legend-rid="lgnd_pone-0002637-g003"><span>Figs. 3A4 &#x00026; 3A7</span></a>) but not in the LC-CD133<sup>&#x02212;</sup> group (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g003" rid-ob="ob-pone-0002637-g003" co-legend-rid="lgnd_pone-0002637-g003"><span>Fig. 3A1</span></a>). Diffuse infiltrations of LC-CD133<sup>&#x0002b;</sup> from the lung parenchyma to the alveolar cavity were observed (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g003" rid-ob="ob-pone-0002637-g003" co-legend-rid="lgnd_pone-0002637-g003"><span>Figs. 3A5, 3A6, and 3A8</span></a>). The histological examination demonstrated that the prominent neovascularization and thrombus formation were detected in the pulmonary parenchyma of LC-CD133<sup>&#x0002b;</sup>-injected SCID mice (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g003" rid-ob="ob-pone-0002637-g003" co-legend-rid="lgnd_pone-0002637-g003"><span>Fig. 3A9</span></a>). In contrast, no significant tumor foci or neovascular formation was found in the lungs of LC-CD133<sup>&#x02212;</sup>-injected SCID mice (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g003" rid-ob="ob-pone-0002637-g003" co-legend-rid="lgnd_pone-0002637-g003"><span>Figs. 3A2 &#x00026; 3A3</span></a>). We further investigated the <em>in vivo</em> tumor growth rate in 10<sup>4</sup> LC-CD133<sup>&#x0002b;</sup> cells, 10<sup>6</sup> LC-CD133<sup>&#x02212;</sup> cells, and 5&#x000d7;10<sup>6</sup> parent tumor cells from the same patient. The finding demonstrated that the tumor growth rate of the 10<sup>4</sup> LC-CD133<sup>&#x0002b;</sup> group (from Patients No. 1, 2, 4, and 7; <a href="/pmc/articles/PMC2440807/table/pone-0002637-t001/" target="table" class="fig-table-link figpopup" rid-figpopup="pone-0002637-t001" rid-ob="ob-pone-0002637-t001" co-legend-rid=""><span>Table 1</span></a>) was significantly higher than that of the 10<sup>6</sup> LC-CD133<sup>&#x02212;</sup> group and 5&#x000d7;10<sup>6</sup> parental tumor cell group (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g003" rid-ob="ob-pone-0002637-g003" co-legend-rid="lgnd_pone-0002637-g003"><span>Fig. 3B</span></a>). Furthermore, 10<sup>4</sup> LC-CD133<sup>&#x0002b;</sup> isolated from secondary tumors can further generate new (second) tumors from transplanted SCID mice. Results of flow cytometry showed that a high percentage (60&#x00025;) of CD133-positive cells was detected in the second tumor (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g003" rid-ob="ob-pone-0002637-g003" co-legend-rid="lgnd_pone-0002637-g003"><span>Fig. 3C</span></a>). In addition, one thousand LC-CD133<sup>&#x0002b;</sup> isolated from the second tumor can also generate a new (third) tumor in transplanted SCID mice (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g003" rid-ob="ob-pone-0002637-g003" co-legend-rid="lgnd_pone-0002637-g003"><span>Fig. 3C</span></a>). To sum, our data indicated that LC-CD133<sup>&#x0002b;</sup> present self-renewing and repopulation capabilities both <em>in vitro</em> and <em>in vivo</em>.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="pone-0002637-g003" co-legend-rid="lgnd_pone-0002637-g003"><a href="/pmc/articles/PMC2440807/figure/pone-0002637-g003/" target="figure" rid-figpopup="pone-0002637-g003" rid-ob="ob-pone-0002637-g003"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139700234522464" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2440807_pone.0002637.g003.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is pone.0002637.g003.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2440807/bin/pone.0002637.g003.jpg" /></a></div><div id="largeobj_idm139700234522464" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2440807/figure/pone-0002637-g003/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_pone-0002637-g003"><div><a class="figpopup" href="/pmc/articles/PMC2440807/figure/pone-0002637-g003/" target="figure" rid-figpopup="pone-0002637-g003" rid-ob="ob-pone-0002637-g003">Figure 3</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Evaluation of the tumorigenicity of LC-CD133<sup>&#x0002b;</sup> and LC-CD133<sup>&#x02212;</sup>\n<em>in vivo</em>.</strong><p id="__p24">(A) The i<em>n vivo</em> tumorigenicity of LC-CD133<sup>&#x0002b;</sup> and LC-CD133<sup>&#x02212;</sup> in tail vein-injected mice was analyzed by macroscopic and histological examination. A1&#x02013;3: LC-CD133<sup>&#x02212;</sup>; arrows: normal alveolar structure of lung. A4&#x02013;6: LC-CD133<sup>&#x0002b;</sup>; arrows: tumor formation. A7&#x02013;9: LC-CD133<sup>&#x0002b;</sup>; arrows: neovascularity and thrombosis. Bar: 200 &#x000b5;m. (B) The <em>in vivo</em> tumor-restoration and proliferative ability of 10<sup>4</sup> LC-CD133<sup>&#x0002b;</sup>, 10<sup>5</sup> LC-CD133<sup>&#x02212;</sup> and 5&#x000d7;10<sup>5</sup> total tumor cells from patient No. 1, 2, 4, and 7 were examined by xenotransplanted tumorigenicity analysis. (C) The tumor repopulation ability of LC-CD133<sup>&#x0002b;</sup> was studied in transplanted SCID mice. The expression levels of CD133 were determined by FACS analysis from primary LC-CD133<sup>&#x0002b;</sup>, second tumor, and third tumor. Data shown here are the mean&#x000b1;SD of three experiments.</p></div></div></div></div><div id="s3d" class="sec"><h3 id="s3dtitle">Enhanced Chemo- and Radiation-resistance in LC-CD133<sup>&#x0002b;</sup>\n</h3><p id="__p25" class="p p-first">We evaluated the multidrug (chemotherapy)-resistant abilities of LC-CD133<sup>&#x0002b;</sup> and LC-CD133<sup>&#x02212;</sup>. We further tested four common chemotherapeutic agents including cisplatin, VP16 (etoposide), doxorubicin, paclitaxel. Compared with LC-CD133<sup>&#x02212;,</sup> LC-CD133<sup>&#x0002b;</sup> are significantly resistant to the four tested chemotherapeutic agents (<em>p</em>&#x0003c;0.01; <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g004/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g004" rid-ob="ob-pone-0002637-g004" co-legend-rid="lgnd_pone-0002637-g004"><span>Fig. 4A</span></a>). To further determine the radiation effect on the rate of tumor growth, we used an ionizing radiation (IR) dose from 0 to 10 Gy to treat both LC-CD133<sup>&#x0002b;</sup> and LC-CD133<sup>&#x02212;</sup>. As shown in <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g003" rid-ob="ob-pone-0002637-g003" co-legend-rid="lgnd_pone-0002637-g003"><span>Fig. 3B</span></a>, after IR treatment, the survival rate and number of LC-CD133<sup>&#x0002b;</sup> were significantly higher than those of LC-CD133<sup>&#x02212;</sup> (<em>p</em>&#x0003c;0.01). We further found that the LC-CD133<sup>&#x0002b;</sup> cells possess a higher degree of radioresistance (<em>p</em>&#x0003c;0.01; <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g004/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g004" rid-ob="ob-pone-0002637-g004" co-legend-rid="lgnd_pone-0002637-g004"><span>Fig. 4B</span></a>). Moreover, we investigated the combined treatment effect of radiochemotherapy in LC-CD133<sup>&#x0002b;</sup>. Experiments were conducted with cisplatin (10 &#x000b5;M) alone, VP-16 (10 &#x000b5;M) alone, or combined cisplatin and VP-16 on IR (2 Gy)-treated LC-CD133<sup>&#x0002b;</sup>. As shown in <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g003" rid-ob="ob-pone-0002637-g003" co-legend-rid="lgnd_pone-0002637-g003"><span>Figure 3C</span></a>, the data revealed that the cell survival rate in IR-treated LC-CD133<sup>&#x0002b;</sup> was not significantly decreased by the IR treatment combined with cisplatin, with or without VP-16 (<em>p</em>&#x0003e;0.05). On the contrary, cell survival significantly declined after chemotherapy with cisplatin combined with VP-16 in IR-treated LC-CD133<sup>&#x02212;</sup> (<em>p</em>&#x0003c;0.01; <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g004/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g004" rid-ob="ob-pone-0002637-g004" co-legend-rid="lgnd_pone-0002637-g004"><span>Fig. 4C</span></a>). These results suggest that LC-CD133<sup>&#x0002b;</sup> may play a vital role in the tumor\'s ability to resist radiation and chemotherapies.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="pone-0002637-g004" co-legend-rid="lgnd_pone-0002637-g004"><a href="/pmc/articles/PMC2440807/figure/pone-0002637-g004/" target="figure" rid-figpopup="pone-0002637-g004" rid-ob="ob-pone-0002637-g004"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139700162868560" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2440807_pone.0002637.g004.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is pone.0002637.g004.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2440807/bin/pone.0002637.g004.jpg" /></a></div><div id="largeobj_idm139700162868560" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2440807/figure/pone-0002637-g004/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_pone-0002637-g004"><div><a class="figpopup" href="/pmc/articles/PMC2440807/figure/pone-0002637-g004/" target="figure" rid-figpopup="pone-0002637-g004" rid-ob="ob-pone-0002637-g004">Figure 4</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Chemodrugs and radiation sensitivity of LC-CD133<sup>&#x0002b;</sup> and LC-CD133<sup>&#x02212;</sup>.</strong><p id="__p26">(A) Both 10,000 LC-CD133<sup>&#x0002b;</sup> and LC-CD133<sup>&#x02212;</sup> were plated in a 96-well plate and treated with various concentrations of cisplatin, VP-16, doxorubicin, and paclitaxel for 24 hours in 10&#x00025; FBS/DMEM/F-12 medium. The survival rate was determined by MTT assay. (B) To determine the radiation effect on the tumor growth rate, an ionizing radiation (IR) dose from 0 to 10 Gy was used to treat LC-CD133<sup>&#x0002b;</sup> and LC-CD133<sup>&#x02212;</sup>. &#x0002a;<em>p</em>&#x0003c;0.01: LC-CD133<sup>&#x0002b;</sup> compared with LC-CD133<sup>&#x02212;</sup>. (C) The combined treatment effect of radiochemotherapy in LC-CD133<sup>&#x0002b;</sup> and LC-CD133<sup>&#x02212;</sup> were further evaluated. The four protocols&#x02014;radiation (2 Gy) only, radiation with cisplatin (10 &#x000b5;M), radiation with VP-16 (10 &#x000b5;M), and radiation with paclitaxel (10 nM)&#x02014;were used. &#x0002a;<em>p</em>&#x0003c;0.01. Data shown here are the mean&#x000b1;SD of three experiments.</p></div></div></div></div><div id="s3e" class="sec"><h3 id="s3etitle">Role of Oct-4 Expression in LC-CD133<sup>&#x0002b;</sup>\n</h3><p id="__p27" class="p p-first">Microarray results suggested that the expression level of Oct-4 self-renewal and stemness gene in LC-CD133<sup>&#x0002b;</sup> was significantly up-regulated than that in LC-CD133<sup>&#x02212;</sup>. To validate this finding, we examined expression of Oct-4 both transcriptionally and translationally. The amounts of Oct-4 transcript and protein of isolated LC-CD133<sup>&#x0002b;</sup> (Patients No.1 [PLC] and No.2 [LLC]) were significantly increased compared with those of LC-CD133<sup>&#x02212;</sup> by real-time RT-PCR and western blotting analysis (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g005/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g005" rid-ob="ob-pone-0002637-g005" co-legend-rid="lgnd_pone-0002637-g005"><span>Figs. 5A and 5B</span></a>). To investigate whether Oct-4 expression plays a role in maintaining self-renewal or cancer stem-like properties in LC-CD133<sup>&#x0002b;</sup>, we used the siRNA method with lentiviral vector for knockdown of Oct-4 expression in LC-CD133<sup>&#x0002b;</sup>. We found it important that the treatment of Oct-4 siRNA in LC-CD133<sup>&#x0002b;</sup> can significantly interfere with the capabilities of spheroid-like bodies (SB) formation (<em>p</em>&#x0003c;0.001; <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g005/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g005" rid-ob="ob-pone-0002637-g005" co-legend-rid="lgnd_pone-0002637-g005"><span>Fig. 5C</span></a>). After 7 days of the Oct-4 siRNA treatment, the SB of LC-CD133<sup>&#x0002b;</sup> could not maintain floating spheres but differentiated into attached epithelial-like cells (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g005/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g005" rid-ob="ob-pone-0002637-g005" co-legend-rid="lgnd_pone-0002637-g005"><span>Fig. 5C</span></a>). In contrast, the treatment of scramble control siRNA did not influence the SB formation capability in LC-CD133<sup>&#x0002b;</sup> (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g005/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g005" rid-ob="ob-pone-0002637-g005" co-legend-rid="lgnd_pone-0002637-g005"><span>Fig. 5C</span></a>). The SB of LC-CD133<sup>&#x0002b;</sup> endogenously expressed strong positive signals for Oct-4 and CD133 (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g005/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g005" rid-ob="ob-pone-0002637-g005" co-legend-rid="lgnd_pone-0002637-g005"><span>Fig. 5D</span></a>). Furthermore, the immunofluorescent results demonstrated that both the CD133 and Oct-4 expressions in LC-CD133<sup>&#x0002b;</sup> were significantly blocked after 7 days of Oct-4 siRNA treatment (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g005/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g005" rid-ob="ob-pone-0002637-g005" co-legend-rid="lgnd_pone-0002637-g005"><span>Fig. 5D</span></a>). FASC assay confirmed that the amount of CD133 was dramatically decreased in Oct-4 siRNA-treated LC-CD133<sup>&#x0002b;</sup> and the percentages of LC-CD133<sup>&#x02212;</sup> were significantly increased in LC-CD133<sup>&#x0002b;</sup> after 7 days of Oct-4 siRNA treatment (<em>p</em>&#x0003c;0.001; <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g005/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g005" rid-ob="ob-pone-0002637-g005" co-legend-rid="lgnd_pone-0002637-g005"><span>Fig. 5E</span></a>). These data suggested that Oct-4 may maintain the properties of primitive stem cells and inhibit the tendency for differentiation in LC-CD133<sup>&#x0002b;</sup>.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="pone-0002637-g005" co-legend-rid="lgnd_pone-0002637-g005"><a href="/pmc/articles/PMC2440807/figure/pone-0002637-g005/" target="figure" rid-figpopup="pone-0002637-g005" rid-ob="ob-pone-0002637-g005"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139700161940544" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2440807_pone.0002637.g005.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is pone.0002637.g005.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2440807/bin/pone.0002637.g005.jpg" /></a></div><div id="largeobj_idm139700161940544" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2440807/figure/pone-0002637-g005/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_pone-0002637-g005"><div><a class="figpopup" href="/pmc/articles/PMC2440807/figure/pone-0002637-g005/" target="figure" rid-figpopup="pone-0002637-g005" rid-ob="ob-pone-0002637-g005">Figure 5</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Up-regulated expressions of Oct-4 mRNA and protein in LC-CD133<sup>&#x0002b;</sup>.</strong><p id="__p28">(A) The amounts of Oct-4 transcripts of isolated LC-CD133<sup>&#x0002b;</sup> were significantly increased compared with those of LC-CD133<sup>&#x02212;</sup> by real-time RT-PCR analyses. (B) Western blott data showed that the protein levels of Oct-4 in LC-CD133<sup>&#x0002b;</sup> isolated from PLC and LLC were also significantly upregulated compared with those of LC-CD133<sup>&#x02212;</sup>. (C) The protein expression of Oct-4 in LC-CD133<sup>&#x0002b;</sup> were effectively blocked by Oct-4 siRNA. Treatment of Oct-4 siRNA in LC-CD133<sup>&#x0002b;</sup> can impede the capabilities of SB formation and further facilitate SB to differentiate into attached epithelial-like cells. Bar: 100 &#x000b5;m. (D) By using immunofluorescent staining, we showed that the protein expression levels of both Oct-4 and CD133 in LC-CD133<sup>&#x0002b;</sup> were significantly diminished after Oct-4 siRNA treatment. Bar: 30 &#x000b5;m. (E) The proportion of LC-CD133<sup>&#x02212;</sup> were significantly increased in Oct-4 siRNA-treated LC-CD133<sup>&#x0002b;</sup> by FACS assay. &#x0002a;<em>p</em>&#x0003c;0.001. Data shown here are the mean&#x000b1;SD of three experiments.</p></div></div></div></div><div id="s3f" class="sec"><h3 id="s3ftitle">Enhanced Chemoradiotherapeutic Sensitivity and Apoptotic Activity in LC-CD133<sup>&#x0002b;</sup> Treated by Oct-4 siRNA</h3><p id="__p29" class="p p-first">To further study the role of Oct-4 in tumor malignancy of LC-CD133<sup>&#x0002b;</sup>\n<em>in vitro</em>, the migration/invasive and soft agar colony assay were used. The results showed that the abilities of the <em>in vitro</em> migratory invasion and colony formation in LC-CD133<sup>&#x0002b;</sup> treated by Oct-4 siRNA were significantly decreased compared with non-treated LC-CD133<sup>&#x0002b;</sup>, or LC-CD133<sup>&#x0002b;</sup> treated with scramble-siRNA (control; <em>p</em>&#x0003c;0.001; <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g006/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g006" rid-ob="ob-pone-0002637-g006" co-legend-rid="lgnd_pone-0002637-g006"><span>Fig. 6A</span></a>). Furthermore, the treatment effect of chemoradiotherapy for the LC-CD133<sup>&#x0002b;</sup> group can be significantly improved by the treatment of Oct-4 siRNA compared with non-treated LC-CD133<sup>&#x0002b;</sup> or LC-CD133<sup>&#x0002b;</sup> treated by scramble-siRNA (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g006/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g006" rid-ob="ob-pone-0002637-g006" co-legend-rid="lgnd_pone-0002637-g006"><span>Fig. 6B</span></a>; <em>p</em>&#x0003c;0.001). In addition, we found that the apoptotic activities of annexin V (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g006/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g006" rid-ob="ob-pone-0002637-g006" co-legend-rid="lgnd_pone-0002637-g006"><span>Fig. 6C</span></a>) and caspase 3 (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g006/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g006" rid-ob="ob-pone-0002637-g006" co-legend-rid="lgnd_pone-0002637-g006"><span>Fig. 6D</span></a>; upper part) were quickly and effectively induced in LC-CD133<sup>&#x0002b;</sup> treated by Oct-4 siRNA after 72 hours. In accordance with the result of cell survival and treatment effects in Oct-4 siRNA-treated LC-CD133<sup>&#x0002b;</sup> (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g006/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g006" rid-ob="ob-pone-0002637-g006" co-legend-rid="lgnd_pone-0002637-g006"><span>Fig. 6B</span></a>), the western blot data further demonstrated that the amounts of activated (cleaved) form of PARP were consistently elevated in LC-CD133<sup>&#x0002b;</sup> treated by Oct-4 siRNA with IR alone or combined with chemotherapy (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g006/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g006" rid-ob="ob-pone-0002637-g006" co-legend-rid="lgnd_pone-0002637-g006"><span>Fig. 6D</span></a>; lower part). Thus, knockdown of Oct-4 expression in LC-CD133<sup>&#x0002b;</sup> can effectively enhance chemoradiosensitivities and apoptotic activities in response to IR and chemotherapy, suggesting that Oct-4 could be a key factor enables LC-CD133<sup>&#x0002b;</sup> to resist radiochemotherapeutic stress.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="pone-0002637-g006" co-legend-rid="lgnd_pone-0002637-g006"><a href="/pmc/articles/PMC2440807/figure/pone-0002637-g006/" target="figure" rid-figpopup="pone-0002637-g006" rid-ob="ob-pone-0002637-g006"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139700195497792" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2440807_pone.0002637.g006.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is pone.0002637.g006.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2440807/bin/pone.0002637.g006.jpg" /></a></div><div id="largeobj_idm139700195497792" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2440807/figure/pone-0002637-g006/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_pone-0002637-g006"><div><a class="figpopup" href="/pmc/articles/PMC2440807/figure/pone-0002637-g006/" target="figure" rid-figpopup="pone-0002637-g006" rid-ob="ob-pone-0002637-g006">Figure 6</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Evaluation of the chemoradiosensitivity and apoptotic activity in the knockdown Oct-4 expression of LC-CD133<sup>&#x0002b;</sup>.</strong><p id="__p30">(A) Migratory invasion ability and colony formation of LC-CD133<sup>&#x0002b;</sup> treated by Oct-4 siRNA was significantly decreased compared with non-Oct-4 siRNA-treated LC-CD133<sup>&#x0002b;</sup> or LC-CD133<sup>&#x0002b;</sup> treated with scramble-siRNA (control; <em>p</em>&#x0003c;0.001). (B) The combined treatment effect of radiochemotherapy in non-Oct-4 siRNA-treated LC-CD133<sup>&#x0002b;</sup>, scramble-siRNA, and Oct-4 siRNA-treated LC-CD133<sup>&#x0002b;</sup> were further evaluated. Three groups of cells were exposed to IR (2 Gy) only or radiation plus cisplatin. The cell survival rate was determined by MTT assay. After 72 hours of Oct-4 siRNA treatment, (C) the percentage of Annexin V-positive cells and (D) the activities of caspase 3 (detected by ELISA assay) in Oct-4 siRNA-treated LC-CD133<sup>&#x0002b;</sup> were significantly increased. (D) The western blot data further showed that PARP was significantly induced in Oct-4 siRNA-treated LC-CD133<sup>&#x0002b;</sup> when exposed to IR alone, cisplatin alone, or IR combined with cisplatin. (&#x0002a;<em>p</em>&#x0003c;0.05: LC-CD133<sup>&#x0002b;</sup> with Oct-4 siRNA plus cisplatin <em>vs.</em> LC-CD133<sup>&#x0002b;</sup> with Oct-4 siRNA only. #<em>p</em>&#x0003c;0.05: LC-CD133<sup>&#x0002b;</sup> with Oct-4 siRNA plus cisplatin and IR <em>vs.</em> LC-CD133<sup>&#x0002b;</sup> with Oct-4 siRNA plus IR). Bar: 50 &#x000b5;m. Data shown here are the mean&#x000b1;SD of three experiments.</p></div></div></div></div><div id="s3g" class="sec sec-last"><h3 id="s3gtitle">Inhibition of <em>In Vivo</em> Tumorgeneic Potential in Oct-4 siRNA-treated LC-CD133<sup>&#x0002b;</sup>\n</h3><p id="__p31" class="p p-first">To investigate the treatment effects of chemoradiotherapy on Oct-4 siRNA-treated LC-CD133<sup>&#x0002b;</sup>, LC-CD133<sup>&#x0002b;</sup> was first transfected by lentivector combined with green fluorescent protein gene (GFP), and then <em>in vivo</em> GFP imaging and histological study were used to monitor the tumor-growth effect. We first injected 10<sup>4</sup> LC-CD133<sup>&#x0002b;</sup>-GFP cells into the subcutaneous sites of nude mice with different treatment protocols. The tumor volumes were significantly decreased in Oct-4 siRNA-treated LC-CD133<sup>&#x0002b;</sup> when exposed to IR alone, cisplatin alone, or IR combined with cisplatin (<em>p</em>&#x0003c;0.01; <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g007/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g007" rid-ob="ob-pone-0002637-g007" co-legend-rid="lgnd_pone-0002637-g007"><span>Fig. 7A</span></a>). To further evaluate the capabilities of tumor invasion and metastasis of LC-CD133<sup>&#x0002b;</sup> treated by different regimens, we injected 10<sup>4</sup> LC-CD133<sup>&#x0002b;</sup>-GFP cells from each treatment groups into the tail vein of SCID mice. The results of <em>in vivo</em> GFP imaging showed that the tumor foci of lung and metastatic lesions in the Oct-4-siRNA-treated LC-CD133<sup>&#x0002b;</sup> groups were significantly lower than those of the LC-CD133<sup>&#x0002b;</sup> without Oct-4-siRNA-treated groups (<em>p</em>&#x0003c;0.01; <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g007/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g007" rid-ob="ob-pone-0002637-g007" co-legend-rid="lgnd_pone-0002637-g007"><span>Fig. 7B</span></a>). In addition, to investigate the treatment effects of Oct-4 expression in LC-CD133<sup>&#x0002b;</sup>\n<em>in vivo</em>, we injected the seven groups with different regimens individually into the tail vein of SCID mice for xenotransplanted tumorigenicity analysis (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g007/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g007" rid-ob="ob-pone-0002637-g007" co-legend-rid="lgnd_pone-0002637-g007"><span>Fig. 7C</span></a>). Immunohistochemistry (IHC) showed that the expression levels of Oct-4 in the lung tumors of LC-CD133<sup>&#x0002b;</sup>-injected SCID mice were highly expressed in comparison with the other treated-groups (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g007/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g007" rid-ob="ob-pone-0002637-g007" co-legend-rid="lgnd_pone-0002637-g007"><span>Fig. 7C</span></a>). Oct-4-IHC levels were significantly decreased in Oct-4 siRNA-treated LC-CD133<sup>&#x0002b;</sup> when exposed to IR alone, cisplatin alone, or IR combined with cisplatin (<em>p</em>&#x0003c;0.01; <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g007/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g007" rid-ob="ob-pone-0002637-g007" co-legend-rid="lgnd_pone-0002637-g007"><span>Fig. 7C</span></a>). Moreover, using combined chemoradiotherapy with the treatment of Oct-4 siRNA, the mean survival rate of the LC-CD133<sup>&#x0002b;</sup> group was significantly prolonged compared with the control or other treated groups (<em>p</em>&#x0003c;0.05; <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g007/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g007" rid-ob="ob-pone-0002637-g007" co-legend-rid="lgnd_pone-0002637-g007"><span>Fig. 7D</span></a>). This <em>in vivo</em> study also confirmed that the treatment effect of chemoradiotherapy for the LC-CD133<sup>&#x0002b;</sup> group can be improved by the treatment of Oct-4 siRNA.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="pone-0002637-g007" co-legend-rid="lgnd_pone-0002637-g007"><a href="/pmc/articles/PMC2440807/figure/pone-0002637-g007/" target="figure" rid-figpopup="pone-0002637-g007" rid-ob="ob-pone-0002637-g007"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139700158568144" class="figure"><a class="inline_block ts_canvas" href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=2440807_pone.0002637.g007.jpg" target="tileshopwindow"><div class="ts_bar small" title="Click on image to zoom"></div><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is pone.0002637.g007.jpg" title="Click on image to zoom" class="tileshop" src="/pmc/articles/PMC2440807/bin/pone.0002637.g007.jpg" /></a></div><div id="largeobj_idm139700158568144" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2440807/figure/pone-0002637-g007/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_pone-0002637-g007"><div><a class="figpopup" href="/pmc/articles/PMC2440807/figure/pone-0002637-g007/" target="figure" rid-figpopup="pone-0002637-g007" rid-ob="ob-pone-0002637-g007">Figure 7</a></div><!--caption a7--><div class="caption"><!--caption a8--><strong>Inhibition of tumorgeneic activity in Oct-4 siRNA-treated LC-CD133<sup>&#x0002b;</sup> with chemoradiotherapy.</strong><p id="__p32">LC-CD133<sup>&#x0002b;</sup>-GFP (10<sup>4</sup>) cells of different treatment groups were injected into the subcutaneous sites of nude mice. (A) The tumor volume and (B) The number of pulmonary tumor nodules were significantly decreased in Oct-4 siRNA-treated LC-CD133<sup>&#x0002b;</sup> when exposed to IR alone, cisplatin alone, or IR combined with cisplatin. Cis: cisplatin; Oct-4i: Oct-4 siRNA. (#<em>p</em>&#x0003c;0.01: LC-CD133<sup>&#x0002b;</sup> treated with Oct-4 siRNA <em>vs.</em> LC-CD133<sup>&#x0002b;</sup>. &#x0002a;<em>p</em>&#x0003c;0.01: LC-CD133<sup>&#x0002b;</sup> treated with Oct-4 siRNA plus cisplatin <em>vs.</em> LC-CD133<sup>&#x0002b;</sup> treated with cisplatin only. &#x0002a;&#x0002a;<em>p</em>&#x0003c;0.01: LC-CD133<sup>&#x0002b;</sup> treated with Oct-4 siRNA plus IR <em>vs.</em> LC-CD133<sup>&#x0002b;</sup> treated with IR only. ##<em>p</em>&#x0003c;0.01: LC-CD133<sup>&#x0002b;</sup> treated with Oct-4 siRNA plus cisplatin and IR <em>vs.</em> LC-CD133<sup>&#x0002b;</sup> with Oct-4 siRNA plus IR). (C) The <em>in vivo</em> tumorgeneic activities of LC-CD133<sup>&#x0002b;</sup>- and LC-CD133<sup>&#x02212;</sup>-injected SCID mice were evaluated by histological review (left upper part). The expression levels of Oct-4 in the lung lesions of LC-CD133<sup>&#x0002b;</sup>-injected SCID mice with the different treatment protocol were studied by immunohistochemistry (IHC). The black arrows indicate the positive signals for Oct-4 expression in the tumors detected by IHC. Bar: 50 &#x000b5;m. (D) Survival analysis of SCID mice injected by LC-CD133<sup>&#x0002b;</sup>, LC-CD133<sup>&#x0002b;</sup> treated with cisplatin, LC-CD133<sup>&#x0002b;</sup> treated with IR, and Oct-4 siRNA-treated LC-CD133<sup>&#x0002b;</sup> groups (IR alone, cisplatin alone, or IR combined with cisplatin). Each group tested six mice (n&#x0200a;=&#x0200a;6). Data shown here are the mean&#x000b1;SD of three experiments.</p></div></div></div></div></div><div id="s4" class="tsec sec"><h2 class="head no_bottom_margin" id="s4title">Discussion</h2><p id="__p33" class="p p-first">Self-renewal and pluripotency are the central features in the definition of embryonic stem cells (ESC), and Oct-4 is a key regulator in this process <a href="#pone.0002637-Boiani1" rid="pone.0002637-Boiani1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399480">[24]</a>&#x02013;<a href="#pone.0002637-Lamb1" rid="pone.0002637-Lamb1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399478">[26]</a>. Oct-4 has been suggested as one of four major factors that render the reprogramming capability of adult cells into germline-competent-induced pluripotent stem cells <a href="#pone.0002637-Okita1" rid="pone.0002637-Okita1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399442">[31]</a>&#x02013;<a href="#pone.0002637-Yu1" rid="pone.0002637-Yu1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399452">[33]</a>. Previous studies also showed that mouse pulmonary stem cells endogenously express Oct-4 <a href="#pone.0002637-Ling1" rid="pone.0002637-Ling1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399444">[34]</a>. Recently, Oct-4 transcript can be consistently detected in human embryonal carcinomas, testicular germ cell tumors, seminomas, and bladder carcinomas <a href="#pone.0002637-Jin1" rid="pone.0002637-Jin1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399446">[35]</a>&#x02013;<a href="#pone.0002637-Gidekel1" rid="pone.0002637-Gidekel1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399451">[38]</a>. The expression of Oct-4 has further been shown in human breast cancer stem-like cells, suggesting that its expression may be implicated in self-renewal and tumorigenesis via activating its downstream target genes <a href="#pone.0002637-Ponti1" rid="pone.0002637-Ponti1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399439">[39]</a>. Herein we reported the isolation of CD133-positive cells (LC-CD133<sup>&#x0002b;</sup>) from clinical tissue samples and lung cancer cell lines. LC-CD133<sup>&#x0002b;</sup> showed strong proliferative and invasive capabilities <em>in vitro</em> and <em>in vivo</em> (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g001/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g001" rid-ob="ob-pone-0002637-g001" co-legend-rid="lgnd_pone-0002637-g001"><span>Figs. 1</span></a>, <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g002" rid-ob="ob-pone-0002637-g002" co-legend-rid="lgnd_pone-0002637-g002"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -0.5em;">,2,</span></span><span>2</span></a>, and <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g003/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g003" rid-ob="ob-pone-0002637-g003" co-legend-rid="lgnd_pone-0002637-g003"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and3).</span></span><span>3</span></a>). LC-CD133<sup>&#x0002b;</sup> also displayed significant resistance to chemotherapeutic agents (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g004/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g004" rid-ob="ob-pone-0002637-g004" co-legend-rid="lgnd_pone-0002637-g004"><span>Fig. 4</span></a>). We also demonstrated that Oct-4 expression was transcriptionally and translationally up-regulated in LC-CD133<sup>&#x0002b;</sup> (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g005/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g005" rid-ob="ob-pone-0002637-g005" co-legend-rid="lgnd_pone-0002637-g005"><span>Fig. 5</span></a>). Indeed, Oct-4 functions as a master switch during differentiation by regulating the pluripotent potential in stem cells <a href="#pone.0002637-Okita1" rid="pone.0002637-Okita1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399465">[31]</a>&#x02013;<a href="#pone.0002637-Yu1" rid="pone.0002637-Yu1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399460">[33]</a>. Using the siRNA method with lentiviral vector for knockdown of Oct-4 expression in LC-CD133<sup>&#x0002b;</sup>, our data showed that the treatment of Oct-4 siRNA can block the sphere formation of LC-CD133<sup>&#x0002b;</sup> and further facilitate LC-CD133<sup>&#x0002b;</sup> to differentiate into LC-CD133<sup>&#x02212;</sup> (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g005/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g005" rid-ob="ob-pone-0002637-g005" co-legend-rid="lgnd_pone-0002637-g005"><span>Fig. 5</span></a>). Furthermore, <em>in vivo</em> animal studies demonstrated the IHC of Oct-4 in the lung tumors of LC-CD133<sup>&#x0002b;</sup>-injected SCID mice were prominently up-regulated, and the total lung tumor volume as well as Oct-4 IHC levels can be significantly decreased in LC-CD133<sup>&#x0002b;</sup>-injected mice by the treatment of Oct-4 siRNA with or without chemoradiotherapy (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g007/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g007" rid-ob="ob-pone-0002637-g007" co-legend-rid="lgnd_pone-0002637-g007"><span>Fig. 7</span></a>). In addition, we showed that increased incidence of Oct-4 expression correlated positively with the advanced stage of 78 lung cancers (<a href="#pone.0002637.s002" rid="pone.0002637.s002" class=" supplementary-material">Figs. S1A&#x02013;C</a>). To our knowledge, this is the first study to show that Oct-4 expression plays a crucial role in maintaining self-renewal and cancer stem-like properties in LC-CD133<sup>&#x0002b;</sup>.</p><p id="__p34">The property of resistance to chemotherapy and irradiation treatment is the major clinical criterion to characterize &#x0201c;cancer stem-like cells (CSCs)&#x0201d; <a href="#pone.0002637-Jordan1" rid="pone.0002637-Jordan1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399459">[6]</a>. The existence of cancer stem-like cells may explain why conventional anti-cancer therapies are able only to suppress or shrink a tumor but often cannot completely eradicate it, resulting in eventual recurrence <a href="#pone.0002637-Jordan1" rid="pone.0002637-Jordan1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399461">[6]</a>, <a href="#pone.0002637-Clarke1" rid="pone.0002637-Clarke1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399466">[40]</a>, <a href="#pone.0002637-Elkind1" rid="pone.0002637-Elkind1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399443">[41]</a>. Consistent with these hypotheses, LC-CD133<sup>&#x0002b;</sup> were significantly resistant to cisplatin, VP16 (eptoposide), doxorubicin, and paclitaxel than LC-CD133<sup>&#x02212;</sup> (<em>p</em>&#x0003c;0.001; <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g004/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g004" rid-ob="ob-pone-0002637-g004" co-legend-rid="lgnd_pone-0002637-g004"><span>Fig. 4</span></a>). Even IR alone or a single chemodrug can effectively inhibit cell growth of LC-CD133<sup>&#x02212;</sup> (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g004/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g004" rid-ob="ob-pone-0002637-g004" co-legend-rid="lgnd_pone-0002637-g004"><span>Fig. 4</span></a>); however, IR treatment combined with cisplatin and VP-16 still failed to cause cell death in treated LC-CD133<sup>&#x0002b;</sup> (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g004/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g004" rid-ob="ob-pone-0002637-g004" co-legend-rid="lgnd_pone-0002637-g004"><span>Fig. 4D</span></a>). To overcome resistance to radiotherapy and chemotherapy in LC-CD133<sup>&#x0002b;</sup>, treatment of Oct-4 siRNA was used and results showed that the knockdown Oct-4 in LC-CD133<sup>&#x0002b;</sup> can significantly improve the anti-cancer effect in single- or combination-treated LC-CD133<sup>&#x0002b;</sup>\n<em>in vitro</em> and <em>in vivo</em> (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g006/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g006" rid-ob="ob-pone-0002637-g006" co-legend-rid="lgnd_pone-0002637-g006"><span>Figs. 6</span></a> and <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g007/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g007" rid-ob="ob-pone-0002637-g007" co-legend-rid="lgnd_pone-0002637-g007"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and7).</span></span><span>7</span></a>). Moreover, the mean survival rate of the LC-CD133<sup>&#x0002b;</sup> group can be significantly prolonged after the treatment of Oct-4 siRNA with IR and chemotherapy (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g007/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g007" rid-ob="ob-pone-0002637-g007" co-legend-rid="lgnd_pone-0002637-g007"><span>Fig. 7</span></a>). Recently, Oct-4 has been suggested to be a protector for survival of ES cells from apoptosis induced by etoposide, UV, or heat shock through the Stat3/Survivin pathway <a href="#pone.0002637-Guo1" rid="pone.0002637-Guo1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399468">[42]</a>. Consistent with this important finding, our results suggest that knockdown of Oct-4 expression can effectively enhance the chemoradiosensitivity of LC-CD133<sup>&#x0002b;</sup> through activating the apoptotic activities of caspase 3 and PARP (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g006/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g006" rid-ob="ob-pone-0002637-g006" co-legend-rid="lgnd_pone-0002637-g006"><span>Fig. 6</span></a>). Importantly, our <em>in vivo</em> animal study and clinical data provide the evidence that the amount of Oct-4 in LC-CD133<sup>&#x0002b;</sup> (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g007/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g007" rid-ob="ob-pone-0002637-g007" co-legend-rid="lgnd_pone-0002637-g007"><span>Fig. 7C</span></a>) and in patients with high-grade lung cancer (<a href="#pone.0002637.s002" rid="pone.0002637.s002" class=" supplementary-material">Fig. S1</a>) is positively correlated with the degree of resistance to chemoradiation therapy. Taken together, these results indicate that the up-regulated expression of Oct-4 in LC-CD133<sup>&#x0002b;</sup> may contribute to the development of chemoradioresistance in patients with lung cancer.</p><p id="__p35">Recent studies have revealed that the human ABCG2 transporter is a P-glycoprotein that causes multidrug resistance (MDR) including mitoxantrone, doxorubicin, and topoisomerase I inhibitors of irinotecan, topotecan, and 7-ethyl-10-hydroxycamptothecin (topoisomerase inhibitor) and gefitinib (an inhibitor of EGF receptor) in patients with lung cancer <a href="#pone.0002637-Elkind1" rid="pone.0002637-Elkind1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399438">[41]</a>, <a href="#pone.0002637-Kawabata1" rid="pone.0002637-Kawabata1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399457">[43]</a>. Hirschmann-Jax and colleagues were the first to observe that &#x0201c;side population&#x0201d; cancer stem-like cells isolated from cell lines and patients with neuroblastoma expressed high levels of ABCG2 and ABCG3 transporter genes as well as a greater capacity to expel cytotoxic drugs <a href="#pone.0002637-HirschmannJax1" rid="pone.0002637-HirschmannJax1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399469">[44]</a>. Monzani and colleagues further showed that cancer stem-like cells derived from the melanoma cell line highly co-expressed CD133 and ABCG2 markers with enhanced tumorigenic potential <a href="#pone.0002637-Monzani1" rid="pone.0002637-Monzani1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_665399450">[45]</a>. In this study, we found that LC-CD133<sup>&#x0002b;</sup> are highly co-expressed with ABCG2 transporter and are significantly resistant to conventional treatment methods compared with LC-CD133<sup>&#x02212;</sup> (<a href="/pmc/articles/PMC2440807/figure/pone-0002637-g002/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g002" rid-ob="ob-pone-0002637-g002" co-legend-rid="lgnd_pone-0002637-g002"><span>Figs. 2</span></a> &#x00026; <a href="/pmc/articles/PMC2440807/figure/pone-0002637-g004/" target="figure" class="fig-table-link figpopup" rid-figpopup="pone-0002637-g004" rid-ob="ob-pone-0002637-g004" co-legend-rid="lgnd_pone-0002637-g004"><span>4</span></a>). Interestingly, a significant down-regulating of ABCG2 expression and an increase in the chemosensitivity of LC-CD133<sup>&#x0002b;</sup> were observed when the Oct-4 siRNA treatment was given (Data not shown). Thus, more studies are needed to investigate whether over-expression of Oct-4, CD133, and/or ABCG2 play a role in the development of MDR in LC-CD133<sup>&#x0002b;</sup> or surrogate markers of therapeutic response in patients with lung cancer.</p><p id="__p36" class="p p-last">In conclusion, we demonstrated that LC-CD133<sup>&#x0002b;</sup> display a higher Oct-4 expression with the ability to self-renew and may represent a reservoir with unlimited proliferative potentials for generating lung cancer cells. The resistance of LC-CD133<sup>&#x0002b;</sup> to <em>in vitro</em> and <em>in vivo</em> chemoradiotherapy is partially due to preferential activation of Oct-4 gene expression. In addition, these data support that the up-regulated expressions of the Oct-4, self-renewing gene of embryonic stem cells, play an important role in the tumorigenicity of patients with lung cancer.</p></div><div id="s5" class="tsec sec"><a id="supplementary-material-sec"></a><h2 class="head no_bottom_margin" id="s5title">Supporting Information</h2><!--/article/body/sec/--><div class="sec suppmat" id="pone.0002637.s001"><h4>Table S1</h4><p id="__p37">(0.05 MB DOC)</p><div class="sup-box half_rhythm" id="idm139700234806224"><a href="/pmc/articles/PMC2440807/bin/pone.0002637.s001.doc" data-ga-action="click_feat_suppl">Click here for additional data file.</a><sup>(46K, doc)</sup></div></div><div class="sec suppmat" id="pone.0002637.s002"><h4>Figure S1</h4><p id="__p39">Correlation of Oct-4 expression levels and the clinical grading and survival rate in the patients with lung cancers. (A) Detection of Oct-4 expression in 78 NSCLC lung cancer patients with different stages by using immunohistochemistry (IHC). Black arrows: positive signals for Oct-4 by IHC. Bar: 50 um. (B) Oct-4 was detected in the almost high grades (III &#x00026; IV) of lung cancer tissues, and significantly expressed the higher intensity of Oct-4-positive signals in grade III &#x00026; IV (high grade) than those in grade I &#x00026; II (low grade) lung cancers patients (p&#x0003c;0.01). (C) Kaplan-Meier analysis of overall survival in 78 lung cancer patients with or without Oct-4 expression.</p><p id="__p40">(7.61 MB TIF)</p><div class="sup-box half_rhythm" id="idm139700234801568"><a href="/pmc/articles/PMC2440807/bin/pone.0002637.s002.tif" data-ga-action="click_feat_suppl">Click here for additional data file.</a><sup>(7.2M, tif)</sup></div></div></div><div id="idm139700234799968" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139700234799968title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="idm139700234799840"><p id="__p42" class="p p-first-last"><strong>Competing Interests: </strong>The authors have declared that no competing interests exist.</p></p><p class="fn sec" id="idm139700161159904"><p id="__p43" class="p p-first-last"><strong>Funding: </strong>This study was supported by research grants from the National Science Council (NSC-96-3111-B-075-001-MY3, 95-2314-B-075-055-MY2, 96-2628-B-010-006-MY3, 96-2314-B-075-024), Taipei Veterans General Hospital (V96C1-151, V96E1-004, V96ER2-016, V96E2-010), the Joint Projects of UTVGH (VGHUST96-P1-07), Yen-Tjing-Ling Medical Foundation, Taipei City Hospital (96001-62-014, 96001-62-018, 96002-62-092), and National Yang-Ming University (Ministry of Education, Aim for the Top University Plan), Taiwan.</p></p></div></div><div id="idm139700161158272" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139700161158272title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="pone.0002637-Spira1">1. <span class="element-citation">Spira A, Ettinger DS. Multidisciplinary management of lung cancer. <span><span class="ref-journal">N Engl J Med. </span>2004;<span class="ref-vol">350</span>:379\xe2\x80\x93392.</span> [<a href="/pubmed/14736930" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Multidisciplinary+management+of+lung+cancer.&amp;author=A+Spira&amp;author=DS+Ettinger&amp;volume=350&amp;publication_year=2004&amp;pages=379-392&amp;pmid=14736930&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Hsu1">2. <span class="element-citation">Hsu HS, Wen CK, Tang YA, Lin RK, Li WY, et al.  Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. <span><span class="ref-journal">Clin Cancer Res. </span>2005;<span class="ref-vol">11</span>:5410\xe2\x80\x935416.</span> [<a href="/pubmed/16061855" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Promoter+hypermethylation+is+the+predominant+mechanism+in+hMLH1+and+hMSH2+deregulation+and+is+a+poor+prognostic+factor+in+nonsmoking+lung+cancer.&amp;author=HS+Hsu&amp;author=CK+Wen&amp;author=YA+Tang&amp;author=RK+Lin&amp;author=WY+Li&amp;volume=11&amp;publication_year=2005&amp;pages=5410-5416&amp;pmid=16061855&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Socinski1">3. <span class="element-citation">Socinski MA, Bogart JA. Limited-stage small-cell lung cancer: the current status of combined-modality therapy. <span><span class="ref-journal">J Clin Oncol. </span>2007;<span class="ref-vol">25</span>:4137\xe2\x80\x934145.</span> [<a href="/pubmed/17827464" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Oncol&amp;title=Limited-stage+small-cell+lung+cancer:+the+current+status+of+combined-modality+therapy.&amp;author=MA+Socinski&amp;author=JA+Bogart&amp;volume=25&amp;publication_year=2007&amp;pages=4137-4145&amp;pmid=17827464&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Bernstein1">4. <span class="element-citation">Bernstein ED, Herbert SM, Hanna NH. Chemotherapy and radiotherapy in the treatment of resectable non-small-cell lung cancer. <span><span class="ref-journal">Ann Surg Oncol. </span>2006;<span class="ref-vol">13</span>:291\xe2\x80\x93301.</span> [<a href="/pubmed/16450219" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Ann+Surg+Oncol&amp;title=Chemotherapy+and+radiotherapy+in+the+treatment+of+resectable+non-small-cell+lung+cancer.&amp;author=ED+Bernstein&amp;author=SM+Herbert&amp;author=NH+Hanna&amp;volume=13&amp;publication_year=2006&amp;pages=291-301&amp;pmid=16450219&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Lam1">5. <span class="element-citation">Lam WK, Watkins DN. Lung cancer: future directions. <span><span class="ref-journal">Respirology. </span>2007;<span class="ref-vol">12</span>:471\xe2\x80\x937.</span> [<a href="/pubmed/17587411" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Respirology&amp;title=Lung+cancer:+future+directions.&amp;author=WK+Lam&amp;author=DN+Watkins&amp;volume=12&amp;publication_year=2007&amp;pages=471-7&amp;pmid=17587411&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Jordan1">6. <span class="element-citation">Jordan CT, Guzman ML, Noble M. Cancer stem cells. <span><span class="ref-journal">N Engl J Med. </span>2006;<span class="ref-vol">355</span>:1253\xe2\x80\x931261.</span> [<a href="/pubmed/16990388" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=N+Engl+J+Med&amp;title=Cancer+stem+cells.&amp;author=CT+Jordan&amp;author=ML+Guzman&amp;author=M+Noble&amp;volume=355&amp;publication_year=2006&amp;pages=1253-1261&amp;pmid=16990388&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Goodell1">7. <span class="element-citation">Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. <span><span class="ref-journal">J Exp Med. </span>1996;<span class="ref-vol">183</span>:1797\xe2\x80\x931806.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2192511/">PMC free article</a>]</span> [<a href="/pubmed/8666936" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Exp+Med&amp;title=Isolation+and+functional+properties+of+murine+hematopoietic+stem+cells+that+are+replicating+in+vivo.&amp;author=MA+Goodell&amp;author=K+Brose&amp;author=G+Paradis&amp;author=AS+Conner&amp;author=RC+Mulligan&amp;volume=183&amp;publication_year=1996&amp;pages=1797-1806&amp;pmid=8666936&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Ho1">8. <span class="element-citation">Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. <span><span class="ref-journal">Cancer Res. </span>2007;<span class="ref-vol">67</span>:4827\xe2\x80\x934833.</span> [<a href="/pubmed/17510412" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Side+population+in+human+lung+cancer+cell+lines+and+tumors+is+enriched+with+stem-like+cancer+cells.&amp;author=MM+Ho&amp;author=AV+Ng&amp;author=S+Lam&amp;author=JY+Hung&amp;volume=67&amp;publication_year=2007&amp;pages=4827-4833&amp;pmid=17510412&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Gutova1">9. <span class="element-citation">Gutova M, Najbauer J, Gevorgyan A, Metz MZ, Weng Y. Identification of uPAR-positive chemoresistant cells in small cell lung cancer. <span><span class="ref-journal">PLoS ONE. </span>2007;<span class="ref-vol">2</span>:e243.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1800348/">PMC free article</a>]</span> [<a href="/pubmed/17327908" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+ONE&amp;title=Identification+of+uPAR-positive+chemoresistant+cells+in+small+cell+lung+cancer.&amp;author=M+Gutova&amp;author=J+Najbauer&amp;author=A+Gevorgyan&amp;author=MZ+Metz&amp;author=Y+Weng&amp;volume=2&amp;publication_year=2007&amp;pages=e243&amp;pmid=17327908&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Yin1">10. <span class="element-citation">Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, et al.  AC133, a novel marker for human hematopoietic stem and progenitor cells. <span><span class="ref-journal">Blood. </span>1997;<span class="ref-vol">90</span>:5002\xe2\x80\x935012.</span> [<a href="/pubmed/9389720" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Blood&amp;title=AC133,+a+novel+marker+for+human+hematopoietic+stem+and+progenitor+cells.&amp;author=AH+Yin&amp;author=S+Miraglia&amp;author=ED+Zanjani&amp;author=G+Almeida-Porada&amp;author=M+Ogawa&amp;volume=90&amp;publication_year=1997&amp;pages=5002-5012&amp;pmid=9389720&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Collins1">11. <span class="element-citation">Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. <span><span class="ref-journal">Cancer Res. </span>2005;<span class="ref-vol">65</span>:10946\xe2\x80\x9310951.</span> [<a href="/pubmed/16322242" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Prospective+identification+of+tumorigenic+prostate+cancer+stem+cells.&amp;author=AT+Collins&amp;author=PA+Berry&amp;author=C+Hyde&amp;author=MJ+Stower&amp;author=NJ+Maitland&amp;volume=65&amp;publication_year=2005&amp;pages=10946-10951&amp;pmid=16322242&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Olempska1">12. <span class="element-citation">Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, et al.  Detection of tumor stem cell markers in pancreatic carcinoma cell lines. <span><span class="ref-journal">Hepatobiliary Pancreat Dis Int. </span>2007;<span class="ref-vol">6</span>:92\xe2\x80\x9397.</span> [<a href="/pubmed/17287174" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Hepatobiliary+Pancreat+Dis+Int&amp;title=Detection+of+tumor+stem+cell+markers+in+pancreatic+carcinoma+cell+lines.&amp;author=M+Olempska&amp;author=PA+Eisenach&amp;author=O+Ammerpohl&amp;author=H+Ungefroren&amp;author=F+Fandrich&amp;volume=6&amp;publication_year=2007&amp;pages=92-97&amp;pmid=17287174&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-OBrien1">13. <span class="element-citation">O\'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. <span><span class="ref-journal">Nature. </span>2007;<span class="ref-vol">445</span>:106\xe2\x80\x93110.</span> [<a href="/pubmed/17122772" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=A+human+colon+cancer+cell+capable+of+initiating+tumour+growth+in+immunodeficient+mice.&amp;author=CA+O\'Brien&amp;author=A+Pollett&amp;author=S+Gallinger&amp;author=JE+Dick&amp;volume=445&amp;publication_year=2007&amp;pages=106-110&amp;pmid=17122772&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Ma1">14. <span class="element-citation">Ma S, Chan KW, Hu L, Lee TK, Wo JY, et al.  Identification and characterization of tumorigenic liver cancer stem/progenitor cells. <span><span class="ref-journal">Gastroenterology. </span>2007;<span class="ref-vol">132</span>:2542\xe2\x80\x932556.</span> [<a href="/pubmed/17570225" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Identification+and+characterization+of+tumorigenic+liver+cancer+stem/progenitor+cells.&amp;author=S+Ma&amp;author=KW+Chan&amp;author=L+Hu&amp;author=TK+Lee&amp;author=JY+Wo&amp;volume=132&amp;publication_year=2007&amp;pages=2542-2556&amp;pmid=17570225&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Singh1">15. <span class="element-citation">Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, et al.  Identification of a cancer stem cell in human brain tumors. <span><span class="ref-journal">Cancer Res. </span>2003;<span class="ref-vol">63</span>:5821\xe2\x80\x935828.</span> [<a href="/pubmed/14522905" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Identification+of+a+cancer+stem+cell+in+human+brain+tumors.&amp;author=SK+Singh&amp;author=ID+Clarke&amp;author=M+Terasaki&amp;author=VE+Bonn&amp;author=C+Hawkins&amp;volume=63&amp;publication_year=2003&amp;pages=5821-5828&amp;pmid=14522905&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Singh2">16. <span class="element-citation">Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al.  Identification of human brain tumour initiating cells. <span><span class="ref-journal">Nature. </span>2004;<span class="ref-vol">432</span>:396\xe2\x80\x93401.</span> [<a href="/pubmed/15549107" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Identification+of+human+brain+tumour+initiating+cells.&amp;author=SK+Singh&amp;author=C+Hawkins&amp;author=ID+Clarke&amp;author=JA+Squire&amp;author=J+Bayani&amp;volume=432&amp;publication_year=2004&amp;pages=396-401&amp;pmid=15549107&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Liu1">17. <span class="element-citation">Liu G, Yuan X, Zeng Z, Tunici P, Ng H, et al.  Analysis of gene expression and chemoresistance of CD133&#x0002b; cancer stem cells in glioblastoma. <span><span class="ref-journal">Mol Cancer. </span>2006;<span class="ref-vol">5</span>:67\xe2\x80\x9378.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1697823/">PMC free article</a>]</span> [<a href="/pubmed/17140455" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Cancer&amp;title=Analysis+of+gene+expression+and+chemoresistance+of+CD133&#x0002b;+cancer+stem+cells+in+glioblastoma.&amp;author=G+Liu&amp;author=X+Yuan&amp;author=Z+Zeng&amp;author=P+Tunici&amp;author=H+Ng&amp;volume=5&amp;publication_year=2006&amp;pages=67-78&amp;pmid=17140455&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Bao1">18. <span class="element-citation">Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. <span><span class="ref-journal">Nature. </span>2006;<span class="ref-vol">444</span>:756\xe2\x80\x93760.</span> [<a href="/pubmed/17051156" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Glioma+stem+cells+promote+radioresistance+by+preferential+activation+of+the+DNA+damage+response.&amp;author=S+Bao&amp;author=Q+Wu&amp;author=RE+McLendon&amp;author=Y+Hao&amp;author=Q+Shi&amp;volume=444&amp;publication_year=2006&amp;pages=756-760&amp;pmid=17051156&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Bruno1">19. <span class="element-citation">Bruno S, Bussolati B, Grange C, Collino F, Graziano ME, et al.  CD133&#x0002b; renal progenitor cells contribute to tumor angiogenesis. <span><span class="ref-journal">Am J Pathol. </span>2006;<span class="ref-vol">169</span>:2223\xe2\x80\x932235.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1762463/">PMC free article</a>]</span> [<a href="/pubmed/17148683" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Am+J+Pathol&amp;title=CD133&#x0002b;+renal+progenitor+cells+contribute+to+tumor+angiogenesis.&amp;author=S+Bruno&amp;author=B+Bussolati&amp;author=C+Grange&amp;author=F+Collino&amp;author=ME+Graziano&amp;volume=169&amp;publication_year=2006&amp;pages=2223-2235&amp;pmid=17148683&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Hilbe1">20. <span class="element-citation">Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E, et al.  CD133 positive endothelial progenitor cells contribute to the tumour vasculature in non-small cell lung cancer. <span><span class="ref-journal">J Clin Pathol. </span>2004;<span class="ref-vol">57</span>:965\xe2\x80\x93969.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1770433/">PMC free article</a>]</span> [<a href="/pubmed/15333659" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Pathol&amp;title=CD133+positive+endothelial+progenitor+cells+contribute+to+the+tumour+vasculature+in+non-small+cell+lung+cancer.&amp;author=W+Hilbe&amp;author=S+Dirnhofer&amp;author=F+Oberwasserlechner&amp;author=T+Schmid&amp;author=E+Gunsilius&amp;volume=57&amp;publication_year=2004&amp;pages=965-969&amp;pmid=15333659&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Eramo1">21. <span class="element-citation">Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, et al.  Identification and expansion of the tumorigenic lung cancer stem cell population. <span><span class="ref-journal">Cell Death Differ. </span>2008;<span class="ref-vol">15</span>:504\xe2\x80\x93514.</span> [<a href="/pubmed/18049477" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell+Death+Differ&amp;title=Identification+and+expansion+of+the+tumorigenic+lung+cancer+stem+cell+population.&amp;author=A+Eramo&amp;author=F+Lotti&amp;author=G+Sette&amp;author=E+Pilozzi&amp;author=M+Biffoni&amp;volume=15&amp;publication_year=2008&amp;pages=504-514&amp;pmid=18049477&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Rosner1">22. <span class="element-citation">Rosner MH, Vigano MA, Ozato K, Timmons PM, Poirier F, et al.  A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo. <span><span class="ref-journal">Nature. </span>1990;<span class="ref-vol">345</span>:686\xe2\x80\x93692.</span> [<a href="/pubmed/1972777" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=A+POU-domain+transcription+factor+in+early+stem+cells+and+germ+cells+of+the+mammalian+embryo.&amp;author=MH+Rosner&amp;author=MA+Vigano&amp;author=K+Ozato&amp;author=PM+Timmons&amp;author=F+Poirier&amp;volume=345&amp;publication_year=1990&amp;pages=686-692&amp;pmid=1972777&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Burdon1">23. <span class="element-citation">Burdon T, Smith A, Savatier P. Signalling, cell cycle and pluripotency in embryonic stem cells. <span><span class="ref-journal">Trends Cell Biol. </span>2002;<span class="ref-vol">12</span>:432\xe2\x80\x93438.</span> [<a href="/pubmed/12220864" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Trends+Cell+Biol&amp;title=Signalling,+cell+cycle+and+pluripotency+in+embryonic+stem+cells.&amp;author=T+Burdon&amp;author=A+Smith&amp;author=P+Savatier&amp;volume=12&amp;publication_year=2002&amp;pages=432-438&amp;pmid=12220864&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Boiani1">24. <span class="element-citation">Boiani M, Scholer HR. Regulatory networks in embryo-derived pluripotent stem cells. <span><span class="ref-journal">Nat Rev Mol Cell Biol. </span>2005;<span class="ref-vol">6</span>:872\xe2\x80\x93884.</span> [<a href="/pubmed/16227977" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Rev+Mol+Cell+Biol&amp;title=Regulatory+networks+in+embryo-derived+pluripotent+stem+cells.&amp;author=M+Boiani&amp;author=HR+Scholer&amp;volume=6&amp;publication_year=2005&amp;pages=872-884&amp;pmid=16227977&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Nichols1">25. <span class="element-citation">Nichols J, Zevnik B, Anastassiadis K, Niwa H, Klewe-Nebenius D, et al.  Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. <span><span class="ref-journal">Cell. </span>1998;<span class="ref-vol">95</span>:379\xe2\x80\x93391.</span> [<a href="/pubmed/9814708" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Formation+of+pluripotent+stem+cells+in+the+mammalian+embryo+depends+on+the+POU+transcription+factor+Oct4.&amp;author=J+Nichols&amp;author=B+Zevnik&amp;author=K+Anastassiadis&amp;author=H+Niwa&amp;author=D+Klewe-Nebenius&amp;volume=95&amp;publication_year=1998&amp;pages=379-391&amp;pmid=9814708&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Lamb1">26. <span class="element-citation">Lamb KA, Rizzino A. Effects of differentiation on the transcriptional regulation of the FGF-4 gene: critical roles played by a distal enhancer. <span><span class="ref-journal">Mol Reprod Dev. </span>1998;<span class="ref-vol">51</span>:218\xe2\x80\x93224.</span> [<a href="/pubmed/9740330" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Reprod+Dev&amp;title=Effects+of+differentiation+on+the+transcriptional+regulation+of+the+FGF-4+gene:+critical+roles+played+by+a+distal+enhancer.&amp;author=KA+Lamb&amp;author=A+Rizzino&amp;volume=51&amp;publication_year=1998&amp;pages=218-224&amp;pmid=9740330&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Kraft1">27. <span class="element-citation">Kraft HJ, Mosselman S, Smits HA, Hohenstein P, Piek E, et al.  Oct-4 regulates alternative platelet-derived growth factor alpha receptor gene promoter in human embryonal carcinoma cells. <span><span class="ref-journal">J Biol Chem. </span>1996;<span class="ref-vol">271</span>:12873\xe2\x80\x9312878.</span> [<a href="/pubmed/8662786" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=Oct-4+regulates+alternative+platelet-derived+growth+factor+alpha+receptor+gene+promoter+in+human+embryonal+carcinoma+cells.&amp;author=HJ+Kraft&amp;author=S+Mosselman&amp;author=HA+Smits&amp;author=P+Hohenstein&amp;author=E+Piek&amp;volume=271&amp;publication_year=1996&amp;pages=12873-12878&amp;pmid=8662786&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Chiou1">28. <span class="element-citation">Chiou SH, Kao CL, Chen YW, Chien CS, Hung SC, et al.  Identification of CD133-positive Radioresistant Cells in Atypical Teratoid/Rhabdoid Tumor. <span><span class="ref-journal">PLoS ONE. </span>2008;<span class="ref-vol">3(5)</span>:e2090.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2396792/">PMC free article</a>]</span> [<a href="/pubmed/18509505" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=PLoS+ONE&amp;title=Identification+of+CD133-positive+Radioresistant+Cells+in+Atypical+Teratoid/Rhabdoid+Tumor.&amp;author=SH+Chiou&amp;author=CL+Kao&amp;author=YW+Chen&amp;author=CS+Chien&amp;author=SC+Hung&amp;volume=3(5)&amp;publication_year=2008&amp;pages=e2090&amp;pmid=18509505&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Yang1">29. <span class="element-citation">Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, et al.  Direct regulation of TWIST by HIF-1alpha promotes metastasis. <span><span class="ref-journal">Nat Cell Biol. </span>2008;<span class="ref-vol">10</span>:295\xe2\x80\x93305.</span> [<a href="/pubmed/18297062" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Cell+Biol&amp;title=Direct+regulation+of+TWIST+by+HIF-1alpha+promotes+metastasis.&amp;author=MH+Yang&amp;author=MZ+Wu&amp;author=SH+Chiou&amp;author=PM+Chen&amp;author=SY+Chang&amp;volume=10&amp;publication_year=2008&amp;pages=295-305&amp;pmid=18297062&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Lee1">30. <span class="element-citation">Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. <span><span class="ref-journal">Cancer Cell. </span>2006;<span class="ref-vol">9</span>:391\xe2\x80\x93403.</span> [<a href="/pubmed/16697959" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Cell&amp;title=Tumor+stem+cells+derived+from+glioblastomas+cultured+in+bFGF+and+EGF+more+closely+mirror+the+phenotype+and+genotype+of+primary+tumors+than+do+serum-cultured+cell+lines.&amp;author=J+Lee&amp;author=S+Kotliarova&amp;author=Y+Kotliarov&amp;author=A+Li&amp;author=Q+Su&amp;volume=9&amp;publication_year=2006&amp;pages=391-403&amp;pmid=16697959&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Okita1">31. <span class="element-citation">Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. <span><span class="ref-journal">Nature. </span>2007;<span class="ref-vol">448</span>:313\xe2\x80\x93317.</span> [<a href="/pubmed/17554338" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Generation+of+germline-competent+induced+pluripotent+stem+cells.&amp;author=K+Okita&amp;author=T+Ichisaka&amp;author=S+Yamanaka&amp;volume=448&amp;publication_year=2007&amp;pages=313-317&amp;pmid=17554338&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Park1">32. <span class="element-citation">Park IH, Zhao R, West JA, Yabuuchi A, Huo H, et al.  Reprogramming of human somatic cells to pluripotency with defined factors. <span><span class="ref-journal">Nature. </span>2008;<span class="ref-vol">451</span>:141\xe2\x80\x93146.</span> [<a href="/pubmed/18157115" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Reprogramming+of+human+somatic+cells+to+pluripotency+with+defined+factors.&amp;author=IH+Park&amp;author=R+Zhao&amp;author=JA+West&amp;author=A+Yabuuchi&amp;author=H+Huo&amp;volume=451&amp;publication_year=2008&amp;pages=141-146&amp;pmid=18157115&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Yu1">33. <span class="element-citation">Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al.  Induced pluripotent stem cell lines derived from human somatic cells. <span><span class="ref-journal">Science. </span>2007;<span class="ref-vol">318</span>:1917\xe2\x80\x931920.</span> [<a href="/pubmed/18029452" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Induced+pluripotent+stem+cell+lines+derived+from+human+somatic+cells.&amp;author=J+Yu&amp;author=MA+Vodyanik&amp;author=K+Smuga-Otto&amp;author=J+Antosiewicz-Bourget&amp;author=JL+Frane&amp;volume=318&amp;publication_year=2007&amp;pages=1917-1920&amp;pmid=18029452&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Ling1">34. <span class="element-citation">Ling TY, Kuo MD, Li CL, Yu AL, Huang YH, et al.  Identification of pulmonary Oct-4&#x0002b; stem/progenitor cells and demonstration of their susceptibility to SARS coronavirus (SARS- CoV) infection in vitro. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2006;<span class="ref-vol">103</span>:9530\xe2\x80\x939535.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1480441/">PMC free article</a>]</span> [<a href="/pubmed/16772384" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&amp;title=Identification+of+pulmonary+Oct-4&#x0002b;+stem/progenitor+cells+and+demonstration+of+their+susceptibility+to+SARS+coronavirus+(SARS-+CoV)+infection+in+vitro.&amp;author=TY+Ling&amp;author=MD+Kuo&amp;author=CL+Li&amp;author=AL+Yu&amp;author=YH+Huang&amp;volume=103&amp;publication_year=2006&amp;pages=9530-9535&amp;pmid=16772384&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Jin1">35. <span class="element-citation">Jin T, Branch DR, Zhang X, Qi S, Youngson B, et al.  Examination of POU homeobox gene expression in human breast cancer cells. <span><span class="ref-journal">Int J Cancer. </span>1999;<span class="ref-vol">81</span>:104\xe2\x80\x93112.</span> [<a href="/pubmed/10077160" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Int+J+Cancer&amp;title=Examination+of+POU+homeobox+gene+expression+in+human+breast+cancer+cells.&amp;author=T+Jin&amp;author=DR+Branch&amp;author=X+Zhang&amp;author=S+Qi&amp;author=B+Youngson&amp;volume=81&amp;publication_year=1999&amp;pages=104-112&amp;pmid=10077160&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Wang1">36. <span class="element-citation">Wang P, Branch DR, Bali M, Schultz GA, Goss PE, et al.  The POU homeodomain protein OCT3 as a potential transcriptional activator for fibroblast growth factor-4 (FGF-4) in human breast cancer cells. <span><span class="ref-journal">Biochem J. </span>2003;<span class="ref-vol">375</span>:199\xe2\x80\x93205.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1223663/">PMC free article</a>]</span> [<a href="/pubmed/12841847" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biochem+J&amp;title=The+POU+homeodomain+protein+OCT3+as+a+potential+transcriptional+activator+for+fibroblast+growth+factor-4+(FGF-4)+in+human+breast+cancer+cells.&amp;author=P+Wang&amp;author=DR+Branch&amp;author=M+Bali&amp;author=GA+Schultz&amp;author=PE+Goss&amp;volume=375&amp;publication_year=2003&amp;pages=199-205&amp;pmid=12841847&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Monk1">37. <span class="element-citation">Monk M, Holding C. Human embryonic genes re-expressed in cancer cells. <span><span class="ref-journal">Oncogene. </span>2001;<span class="ref-vol">20</span>:8085\xe2\x80\x938091.</span> [<a href="/pubmed/11781821" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Oncogene&amp;title=Human+embryonic+genes+re-expressed+in+cancer+cells.&amp;author=M+Monk&amp;author=C+Holding&amp;volume=20&amp;publication_year=2001&amp;pages=8085-8091&amp;pmid=11781821&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Gidekel1">38. <span class="element-citation">Gidekel S, Pizov G, Bergman Y, Pikarsky E. Oct-3/4 is a dose-dependent oncogenic fate determinant. <span><span class="ref-journal">Cancer Cell. </span>2003;<span class="ref-vol">4</span>:361\xe2\x80\x93370.</span> [<a href="/pubmed/14667503" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Cell&amp;title=Oct-3/4+is+a+dose-dependent+oncogenic+fate+determinant.&amp;author=S+Gidekel&amp;author=G+Pizov&amp;author=Y+Bergman&amp;author=E+Pikarsky&amp;volume=4&amp;publication_year=2003&amp;pages=361-370&amp;pmid=14667503&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Ponti1">39. <span class="element-citation">Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, et al.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. <span><span class="ref-journal">Cancer Res. </span>2005;<span class="ref-vol">65</span>:5506\xe2\x80\x935511.</span> [<a href="/pubmed/15994920" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Isolation+and+in+vitro+propagation+of+tumorigenic+breast+cancer+cells+with+stem/progenitor+cell+properties.&amp;author=D+Ponti&amp;author=A+Costa&amp;author=N+Zaffaroni&amp;author=G+Pratesi&amp;author=G+Petrangolini&amp;volume=65&amp;publication_year=2005&amp;pages=5506-5511&amp;pmid=15994920&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Clarke1">40. <span class="element-citation">Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, et al.  Cancer Stem Cells&#x02013;Perspectives on Current Status and Future Directions: AACR Workshop on Cancer Stem Cells. <span><span class="ref-journal">Cancer Res. </span>2006;<span class="ref-vol">66</span>:9339\xe2\x80\x939344.</span> [<a href="/pubmed/16990346" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Cancer+Stem+Cells&#x02013;Perspectives+on+Current+Status+and+Future+Directions:+AACR+Workshop+on+Cancer+Stem+Cells.&amp;author=MF+Clarke&amp;author=JE+Dick&amp;author=PB+Dirks&amp;author=CJ+Eaves&amp;author=CH+Jamieson&amp;volume=66&amp;publication_year=2006&amp;pages=9339-9344&amp;pmid=16990346&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Elkind1">41. <span class="element-citation">Elkind NB, Szentp&#x000e9;tery Z, Ap&#x000e1;ti &#x000c1;, Ozvegy-Laczka C, V&#x000e1;rady G, et al.  Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). <span><span class="ref-journal">Cancer Res. </span>2005;<span class="ref-vol">65</span>:1770\xe2\x80\x931777.</span> [<a href="/pubmed/15753373" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Res&amp;title=Multidrug+transporter+ABCG2+prevents+tumor+cell+death+induced+by+the+epidermal+growth+factor+receptor+inhibitor+Iressa+(ZD1839,+Gefitinib).&amp;author=NB+Elkind&amp;author=Z+Szentp&#x000e9;tery&amp;author=&#x000c1;+Ap&#x000e1;ti&amp;author=C+Ozvegy-Laczka&amp;author=G+V&#x000e1;rady&amp;volume=65&amp;publication_year=2005&amp;pages=1770-1777&amp;pmid=15753373&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Guo1">42. <span class="element-citation">Guo Y, Mantel C, Hromas RA, Broxmeyer HE. Oct-4 is critical for survival/antiapoptosis of murine embryonic stem cells subjected to stress: effects associated with Stat3/survivin. <span><span class="ref-journal">Stem Cells. </span>2008;<span class="ref-vol">26</span>:30\xe2\x80\x9334.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2818886/">PMC free article</a>]</span> [<a href="/pubmed/17932422" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Stem+Cells&amp;title=Oct-4+is+critical+for+survival/antiapoptosis+of+murine+embryonic+stem+cells+subjected+to+stress:+effects+associated+with+Stat3/survivin.&amp;author=Y+Guo&amp;author=C+Mantel&amp;author=RA+Hromas&amp;author=HE+Broxmeyer&amp;volume=26&amp;publication_year=2008&amp;pages=30-34&amp;pmid=17932422&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Kawabata1">43. <span class="element-citation">Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, et al.  Expression and functional analyses of breast cancer resistance protein in lung cancer. <span><span class="ref-journal">Clin Cancer Res. </span>2003;<span class="ref-vol">9</span>:3052\xe2\x80\x933057.</span> [<a href="/pubmed/12912956" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Clin+Cancer+Res&amp;title=Expression+and+functional+analyses+of+breast+cancer+resistance+protein+in+lung+cancer.&amp;author=S+Kawabata&amp;author=M+Oka&amp;author=H+Soda&amp;author=K+Shiozawa&amp;author=K+Nakatomi&amp;volume=9&amp;publication_year=2003&amp;pages=3052-3057&amp;pmid=12912956&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-HirschmannJax1">44. <span class="element-citation">Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, et al.  A distinct &#x0201c;side population&#x0201d; of cells with high drug efflux capacity in human tumor cells. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2004;<span class="ref-vol">101</span>:14228\xe2\x80\x9314233.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC521140/">PMC free article</a>]</span> [<a href="/pubmed/15381773" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S+A&amp;title=A+distinct+&#x0201c;side+population&#x0201d;+of+cells+with+high+drug+efflux+capacity+in+human+tumor+cells.&amp;author=C+Hirschmann-Jax&amp;author=AE+Foster&amp;author=GG+Wulf&amp;author=JG+Nuchtern&amp;author=TW+Jax&amp;volume=101&amp;publication_year=2004&amp;pages=14228-14233&amp;pmid=15381773&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="pone.0002637-Monzani1">45. <span class="element-citation">Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, et al.  Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. <span><span class="ref-journal">Eur J Cancer. </span>2007;<span class="ref-vol">43</span>:935\xe2\x80\x93946.</span> [<a href="/pubmed/17320377" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Eur+J+Cancer&amp;title=Melanoma+contains+CD133+and+ABCG2+positive+cells+with+enhanced+tumourigenic+potential.&amp;author=E+Monzani&amp;author=F+Facchetti&amp;author=E+Galmozzi&amp;author=E+Corsini&amp;author=A+Benetti&amp;volume=43&amp;publication_year=2007&amp;pages=935-946&amp;pmid=17320377&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2440807&amp;issue-id=167827&amp;journal-id=440&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div></div></div></div><!--post-content--><div class="courtesy-note whole_rhythm small"><hr />Articles from <span class="acknowledgment-journal-title">PLoS ONE</span> are provided here courtesy of <strong>Public Library of Science</strong></div></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id="rightcolumn" class="four_col col last">\n        <!-- Custom content above discovery portlets -->\n        <div class="col6">\n            \n        </div>\n        \n        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC2440807/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC2440807/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC2440807/pdf/pone.0002637.pdf">PDF (850K)</a></li> | <li><a href="#" data-citationid="PMC2440807" class="citationexporter ctxp">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2440807%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook" />\n                             Facebook\n                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2440807%2F&amp;text=Oct-4%20Expression%20Maintained%20Cancer%20Stem-Like%20Properties%20in%20Lung%20Cancer-Derived%20CD133-Positive%20Cells"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter" />\n                             Twitter\n                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2440807%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id="ajax-portlets" data-pmid="18612434" data-aiid="2440807" data-aid="2440807" data-iid="167827" data-domainid="440" data-domain="plosone" data-accid="PMC2440807" data-md5="4e1b1d7bd5a84fe1432ef6798631ae78"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class="col7">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class="col8">\n    \n</div>\n<div class="col9">\n    \n</div>\n\n<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>\n<script>\n    (function($){\n        $(\'.skiplink\').each(function(i, item){\n            var href = $($(item).attr(\'href\'));\n            href.attr(\'tabindex\', \'-1\').addClass(\'skiptarget\'); // ensure the target can receive focus\n            $(item).on(\'click\', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id="body-link-poppers"></div>\n                        </div>\n                        <div class="bottom">\n                            \n                            <div id="NCBIFooter_dynamic">\n    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>\n    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2020-04-17T09:44:53-04:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=ptpmc102&amp;ncbi_phid=8A1BFDA3E99AA9510000000005720570&amp;ncbi_session=8A1BFDA3E99B2D41_1394SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2440807%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>\n    \n</div>\n\n                            <div class="footer" id="footer">\n    \n    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>\n    <div id="external-disclaimer" class="offscreen_noflow">\n        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.\n    </div>    \n    <div id="ncbifooter" class="contact_info">      \n        <div id="footer-contents-right">\n            <div id="nlm_thumb_logo">\n                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>\n            </div>\n            <div id="nih_thumb_logo">\n                <a href="https://www.nih.gov" title="NIH">NIH</a>\n            </div>\n            <div id="hhs_thumb_logo">\n                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>\n            </div>\n            <div id="usagov_thumb_logo">\n                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id="footer-contents-left">\n            <p class="address vcard">\n                <span class="url">\n                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>\n                <span class="adr">\n                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>\n                    <span class="region">MD</span>, <span class="postal-code">20894</span>\n                    <span class="country-name">USA</span>\n                </span>\n            </p>\n            \n            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>\n        </div>\n    </div>\n    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    \n    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class="PAFAppResources"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=plosone&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2440807/&amp;ncbi_app=pmc" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id="PageFixtures" label="styles"></component>-->\n    \n\n<!-- 8A1BFDA3E99B2D41_1394SID /projects/PMC/PMCViewer@4.46 ptpmc102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->\n\n<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script></body>\n</html>'